Campylobacter Infection as a Trigger for Guillain Barre Syndrome in Egypt
麻醉英文词汇
麻醉英文词汇 A abortive measles virus 缺损麻疹病毒acidosis 酸中毒,酸血症acquired immune deeficiency syndrome(ALDS) 获得性免疫缺损隐综合征(艾滋病)acute lymphadenitis 急性淋巴结炎acute myelitis 急性脊髓炎acute polyneuroradiculitis 感染性多发性神经根炎acyclovir 无环鸟苷adenosine arabinoside(Ara—A) 阿糖腺苷adherence factor 粘附因子agglutination test 凝集试验alanine aminotransferase(ALT) 丙氨酸转氨酶albumincytological dissociation 蛋白细胞分离allergy 变态反应alternative pathway 替代途径amebic dysentery 阿米巴痢疾amebiasis;amebosis 阿米巴病ameboma 阿米巴瘤amodiaquine dihydrochloridum (二)盐酸氨酚喹啉amoeba histolytica 溶组织阿米巴amoebic liver abscess 阿米巴肝脓肿amoxicillin 羟氨苄青霉素amphoterincin B 两性霉素B ampicilln 氨苄青霉素anaerobic bacteria;anaerobe 厌氧菌anoxemia 缺氧血症anoxia 缺氧ansamycin 袢霉素anthrax 炭疽antibiotic 抗生素antibody 抗体antibody dependent cell-mediated cytotoxicity 抗体依赖细胞介导的细胞毒antigen 抗原antigeic drift 抗原漂移antigenic shift 抗原转移antioxin 抗毒素apparent infection 显性感染arachidonic acid 花生四烯酸Ascoli’s test 炭疽环状沉淀试验asphyxia 窒息aspiration of sputum 吸痰atypical form 非典型型atypical measles 异型麻疹autoimmunity 自身免疫 B bacillary dysentery 细菌性痢疾bacteremia 菌血症bacterium(Pl.bacteria) 细菌bacertial culture 细菌培养bacteral food poisoning 细菌性食物中毒bacterial infectious diseades 细菌性传染病basal diet 基础饮食biopsy 活组织检查bleeding tendency 出血倾向biologicals 生物制品biphasic fever 双相热blood picture;blood figure 血像bloody stool 血便bordetella 鲍特杆菌属borrelia 包柔氏螺旋体属borrlia obermeieri 欧伯门亚螺旋体borrelia recurrentis 回归热螺旋体botulism 肉毒中毒Brill-Zinsser disease 勃秦氏病(复发性斑疹伤寒)brucellosis 布鲁氏菌病brudzinski’s sign 布鲁辛征Brugia malayi 马来丝虫brugia timori 帝纹丝虫Ccampylibacter 弯曲菌campylobacter coli 结肠弯曲菌campylobacter enteritis 弯曲菌肠炎campylobacter fitus 胎儿弯曲菌camyplobacter genus 弯曲菌属campylobacter jejuni 空肠弯曲菌campylobacter jejuni enteritis 空肠弯曲菌肠炎campylobacter laridis 海欧弯曲菌campylobacter pybridis 幽门弯曲菌campylobacter aputorum 唾液弯曲菌carbenicillin 羧苄青霉素carrier 病原携带者carrier state 病原携带状态cefazolin 头孢唑啉cefoperazone(cefobid) 头孢氧哌羟苯唑(先峰必)ceftrizxone 头孢三嗪噻肟cefuroxime 头孢呋肟cellular immunity 细胞免疫cephalothin 头孢噻吩cephalosporin 头孢菌素cercarial dermatitis 尾蚴怀皮炎cestodiasis 绦虫病chickenpox;varicella 水痘chloroquine phosphate 磷酸氯喹Cholera 霍乱chronic active hepatitis(CAH) 慢性活动性肝炎chronic asymptomatic HBv carriers 慢性无症状乙型肝炎病毒携带者chronic persistent hepatitis(CPH) 慢性迁延性肝炎chyluria 乳糜尿circumoral pallor 口围苍白classical pathway 经典途径clindamycin 氯林可霉素clinical pattern 临床类型cloxaillin 邻氯青霉素clostridium botulinum 肉毒杆菌clostrdium botulinum food poisoning 肉毒杆菌食物中毒clostridium perfringens 产气荚膜杆菌communicable disease 传染病complement 补体complenent fixation test(CFT) 补体结合试验complication 并发症comvalescent stage 恢复期convalescence 恢复期coombs’test 抗人球蛋白试验coxiella burnetii 作纳特氏立克次体critical stage 极期cytotoxin 细胞毒素Ddehydration 脱水dingue fever 登革热dengue hemorrhagic fever 登革出血热diarrhea 腹泻dicloxacillin 双氯青霉素dipetalonema perstans 常现丝虫dipetalonema slreptocera 链尾丝虫diphtheria 白喉dipterex 敌百虫disseminated intravascular coagulation(DIC) 播散性血管内凝血diuresis 多尿double-rised fever 双峰热drunken features 酒醉面貌dysentery bacilli 痢疾杆菌Eecchymosis 瘀斑econazde 益康唑elephantiasis 象皮肿enanthema 粘膜疹encephalitis B Japanica 日本乙型脑炎endotoxin 肉毒素enterotoxin 肠毒素enteropathogenic Escherichia coli 致病性大肠杆菌enzyme-linked immunosorbent assay(ELISA) 酶联免疫吸附试验epidimic 流行epidemic cerebrospinal meningitis 流行性脑脊髓膜炎epidemic encephalitis B 流行性乙型脑炎epidemic hemorragic fever(EHF) 流行性出血热epidemic parotitis 流行性腮腺炎epidemic tyhus 流行性斑疹伤寒epididymitis 附睾炎eruption 发疹翻译公司erythrocytic stage 红细胞内期erythogenic toxin 红疹毒素etiology 病原学exanthema subitum 幼儿急疹exoerythrocytic stage 红细胞外期exotoxin 外毒素Ffamilial periodic paralysis 家族性周期性麻痹fecal-oral transmission 粪一口途径传播filarial fever 丝虫热filariasis 丝虫热flavivirus 黄热病毒属(登革热)forest encephalitis 森林脑炎furopromide 呋喃丙胺fusion protein 融合蛋白Ggancyclovir 丙氧鸟苷general teratment 一般治疗giardiasis 贾第鞭毛虫病globoroseomycin 球红霉素GM1ganglioside 单涎酸神经节苷脂Guillain-Barre syndrome 感染性多发性神经根炎Hhaemolysin(HL) 血溶素hantaan virus 汉坦病毒HBcAg 乙型肝炎核心抗原HBeAg 乙型肝炎e抗原HBsAg 乙型肝炎表面抗原Hecht’s giant-cell pneumonia 麻疹巨细胞肺炎hemagglutini 血凝素hemorrhagic fever with renal syndrome(HFRS) 肾综合症出血热hemorrhagic nephroso-nephritis(HNN) 出血热肾病肾炎hepadnaviridae 嗜肝病毒种hepatitisA 甲型肝炎hepatitisB 乙型肝炎hepatitisC 丙型肝炎hepatitisD 丁型肝炎hepatitisE 戊型肝炎herpes-zoster 带状疱疹Herxheimer reaction 赫氏反应heterophil agglutination test 嗜异凝集试验human immunodeficiency virus(HIV) 人类免疫缺陷病毒human rotavirus(HRV) 人类轮状病毒human T-lymphotropic virusⅢ(HTLV-Ⅲ) 人类嗜T淋巴细胞病毒Ⅲ型hydrocele 鞘膜腔积液hydrophabia 恐水病,狂犬病hydroxypiperaquine 羟基哌喹hydroxypiperquine phosphate 磷酸羟基哌喹hypervolemic syndrome 高血容量综合征IimmuneRNA(iRNA) 免疫核糖核酸immunoblotting 免疫转印immunomodulator 免疫调节剂immunoglobulin(IG) 免疫球蛋白inapparent infection 隐性感染infection 传染,感染infectious disease 传染病infectious mononucleosis 传染性单核细胞增多症influenza 流行性感染interferon 干扰素interleukin-2 白细胞介素—2intestinal amebiasis 阿米巴痢疾Ixodes dammini 丹明尼硬蜱Ixodes pacificus 太平洋硬蜱Ixodes persulcatus 森林硬蜱,金硬蜱Ixodes ricinus 蓖子硬蜱Jjaundice 黄疽KKala-azar 黑热病Kanagawa test 神奈川试验Kaposi’s sarcoma 卡波剂氏肉瘤ketoconazole 酮康唑Kering’s sign 克尼格征Killer cell 杀伤细胞Koplid’s spot s 柯氏斑Korean hemorrhagic fever(KHF) 朝鲜出血热LLassa fever 拉沙热latent infection 潜伏性感染Ligionella pneumohpillia 嗜肺军团杆菌Legionnaires’disease 军团病Leishmania donovani 杜氏利什曼原虫lentivirus 慢病毒leptospirosis 钩端螺旋体病leucotriene(LT) 白烯limulus lysate test(LLT) 鲎血溶解物试验lyncomycin 林可霉素lipopolysaccharide(LPS) 脂多糖Lou loa 罗可丝虫LPS-binding protein 脂多糖结合蛋白lyme disease 莱姆病lymph scrotum 阴囊淋巴肿lymphadenitis 淋巴结炎lymphadenovarix 淋巴结肿大lymphadenopathy associated virus(LAV) 淋巴结病相关病毒lymphangivarix 淋巴管曲张lymphangitis 淋巴管炎lysozyme 溶菌酶Mmalaria 疟疾malarial pigment 疟色素mansonella ozzardi 孟欧丝虫measles 麻疹meflquine hydrochloridum 盐酸甲氟酸meningocin 脑膜炎双球菌细菌素merozoite 裂殖子methicillin 甲氧苯青霉素methimidol 盐酸甲唑醇miconazole 咪康唑microfilaria 微丝蚴mumps 流行性腮腺炎murine typhus 鼠型斑疹伤寒Nnafcillin 乙氧萘青霉素naloxone 钠络酮nature killer cell 自然杀伤细胞negri body 内基小体meuraminidase 神经氨酸酶neuronophagia 噬神经细胞现象nithiocyamine 硝硫氰胺nitric oxide 氧化亚氮nitropuine 硝喹nontyphoidal salmonellosis 非伤寒沙门氏菌感染norfloxacin 氟哌酸nosocomial infection 医院内感染nystatin 制霉菌素Ooliguria 少尿onchocerca volvulus 盘尾丝虫orchitis 睾丸炎orntthodoros 媒介昆虫软体蜱,纯缘蜱属open rdad frame 开放性读框opiod 阿片炎outbreak 暴发ovale malaria 卵形疟oxacillin 苯唑青霉素Ppararosamilline pamoate 双羟萘酸副品红paratyphoid fever 副伤寒penicillin G benzathine 苄星青霉素G pentamidine 戊脘脒pepticloglycan 肽糖酐periodicity 周期性peroral 经口的pertussis 百日咳pestis 鼠疫petechia 瘀点pipemidic acid 吡哌酸piperapuine 哌喹piperaquine phosphate 磷酸哌喹plague 鼠疫plasma protamine paracoagulation 血浆鱼精蛋白副凝试验pokinete 动合子poliomyelitis 脊髓灰质炎poliovirus 脊髓灰质炎病毒poly human serum albumine receptor 聚合人血清白蛋白poly I:C 聚肌胞polymerase chain reaction 聚合酶链反应ponteac fever 庞提阿克热post diphtherlc patalysis 白喉后麻痹primunition 相对免疫,带虫免疫primaquine 伯氨喹properdin 备解素prostaglandin 前列腺素prostacyclin 前列环素proviral DNA 前病毒DNApulmonary filariasis 肺型丝虫病pyemia 脓毒症pyquiton 吡喹酮pyracrine phosphate 磷酸咯啶pyronaridine phosphate 磷酸咯萘啶QQ fever Q热quartan malaria 三日疟quinine sulfate 硫酸奎宁Rrabies 狂犬病翻译公司rdlapse 复发relapsing fever 回归热related vibrios 相关弧菌remittent fever 弛张热remittent stage 缓解期repeated infection 重复感染reservoir host 贮存宿主retrovirus 人类逆转录病毒ribavirin 三氮唑核苷rickettsemia 立克次体血症rickettsia 立克次体rickettsia buretii 伯纳特立克次体rickettsia mooseri 莫氏立克次体rickettsia ortientalis 东方立克次体rickettsia prowazekii 普氏立克次体rickettsia tsutsugamushi 恙虫病立克次体rickettsiosis 立克次体病roseola infantum 幼儿急疹rubella 风疹rubeola 麻疹Russion spring-summer encephatitis 苏联春夏型脑炎,森林脑炎Ssalmonella typhimurium 鼠伤寒沙门氏菌scarlet fever 猩红热schistosomiasis 血吸虫病schizont 裂殖体septicemia 败血症septic shock 感染性休克Shwartzmans reaction 施瓦茨曼反应S chick’s test 锡克试验smallpox 天花sodium antimony subgallate 没食子酸锑钠source of infection 传染源spirochetemia 螺旋体血症sterillization 消毒street virus 街毒subacute scletosing panencephalitis(SSPE) 亚急性硬化性全脑炎subclinical infection 亚临床感染subtertain malaria 恶性疟sudden infant death syndrome(SIDS) 婴儿猝死综合征superinfection 重复感染supportive treatment 支持疗法susceptibility of masses 人群易感性syphilis 梅毒Tteichoic acid 菌壁磷壁酸temporary carrier 暂时携带者tertian malaria 间日疟thrombcxane 血栓素togaviridae 披膜病毒科(登革热)toxemia 毒血症Tropical splenomegaly syndrome 热带巨脾综合征tsutsugamushi diseade 恙虫病tularimia 兔热病,土拉菌病typhoid fever 伤寒Uuncinariasis 钩虫病undulant fever 波状热Vvaccine 疫苗vanishing of the rashes 退疹varicella 水痘varicella zoster virus,VZV 水痘带状疱疹病毒vector 媒介vertical transmission 垂直传播vibrio cholerae 霍乱弧菌vibrio fetus 胎儿弧菌vibrio eltor 爱尔托弧菌viral gastroenteritis 病毒性胃肠炎viral hepatitis 病毒性肝炎viremia 病毒血症virulence 毒务visceral leishmaniasis 内脏利什曼病WWarthin-Finkeldey cells 华佛细胞Warerhouse-Friderichsen Syndrome 华佛氏综合Weil-Felix rdaction 外斐氏反应whooping cough 百日咳Widal reacteon 肥达氏反应Wuchereria bancrofti 斑氏丝虫Yyaws 雅司病yellow fever 黄热病Zzygote 合子zymosan 酵母多糖advanced life support ( ALS) /[d5va:nst laif s[5pC:t/ 进一步生命支持allergic reaction (Anaphylactic reaction) /[5l\:dVik ri:5AkF([)n (7An[fi5lAktik)/ 过敏反应anesthesia induction /7An[s5Wi:zi[ in5dQkF([)n/ 麻醉诱导anesthesiology /5Anis7Wi:zi5Rl[dVi/ 麻醉学aspiration /7Asp[5reiF([)n/ 误吸balanced anesthesia /5bAl[nsd 7An[s5Wi:zi[/ 平衡麻醉basic life support ( BLS) /5beisik laif s[5pC:t/ 基本生命支持brachial plexus block /5breiki[l 5pleks[s blCk/ 臂丛阻滞Cardiopulmonary Cerebral Resuscitation /7ka:di[u5pQlm[n[ri 5seribr([)l (s[5ri:br[l) ri7sQsi5teiF[n/ 心肺脑复苏caudal anesthesia /5kC:d([)l 7An[s5Wi:zi[/ 骶麻central venous pressure (CVP) /5sentr([)l 5vi:n[s 5preF[(r)/ 中心静脉压cervical nerve block /s[5vaik([)l (5s\:vik([)l 5n\:v blCk/ 颈丛阻滞endotracheal intubation /7end[u5treiki[l 7intju:5beiF[n/ 气管内插管epidural anesthesia /7epi5dju[r([)l 7An[s5Wi:zi[/ 硬膜外麻醉external chest compression /ek5st\:n([)l tFest k[m5preF([)n/ 胸外按压general anesthesia /5dVen[r[l 7An[s5Wi:zi[/ 全麻hypoxemia /7haipCk5si:mi[/ 低氧血症hypoxia /hai5pCksi[/ 缺氧infiltration anesthesia /7infil5treiF[n 7An[s5Wi:zi[/ 浸润麻醉inhalational anesthesia /7inh[leiF[n[l 7An[s5Wi:zi[/ 吸入全麻Intensive Care Unit (ICU) /in5tensiv ke[(r) 5ju:nit/ 重症监护治疗室local anesthetic /l[uk[l 7An[s5Wetik/ 局麻药muscle relaxants /5mQs([)l ri5lAks[nt/ 肌松剂premedication/pri7medi5keiF[n/ 术前药prolonged life support ( PLS) /pr[5lCNd laif s[5pC:t/ 延续生命支持regional anesthesia /5ri:dV[n([)l 7An[s5Wi:zi[/ 局部麻醉(部位麻醉) spinal anesthesia/5spain([)l 7An[s5Wi:zi[/ 脊麻( 腰麻) total intravenous anesthesia (TIVA) /5t[ut([)l 7intr[5vi:n[s 7An[s5Wi:zi[/ 全凭静脉麻醉toxic reaction /5tCksik ri:5AkF([)n/ 毒性反应urinary retention/5ju[rin[ri ri5tenF([)n/ 尿潴留医药词汇分类:麻醉专业英语词汇<SPAN class=t_msgfont class1="smalltxt"><SPAN class=bold>麻醉专业词汇</SPAN></SPAN><BR><DIV class=t_msgfont id=message112429>A<BR>abate 减轻,减少<BR>abatement 减轻<BR>abbreviated 缩短的,省略的<BR>abdomen 腹部<BR>abdominal 腹部的<BR>abdominal breathing 腹式呼吸<BR>abdominal delivery 剖腹产<BR>abdominal hysterectomy procedure 经腹子宫切除手术<BR>abdominal respiration 腹式呼吸<BR>abdominal section 剖腹术<BR>abdominalgia 腹痛<BR>abdominoscopy 腹腔镜检查<BR>abdominothoracic 胸腹的<BR>abdominouterectomy 腹式子宫切除术<BR>ablation脱离,部分切除(术)<BR>abnormal sensation感觉异常<BR>abolition of reflex 反射消失<BR>aboulia意识缺失<BR>abrosia 禁食<BR>abscess 脓肿<BR>absent respiration 呼吸音消失,无呼吸音呼吸<BR>absolute arrhythmia 绝对心律不齐<BR>absolute diet 禁食,绝食<BR>absolute temperature 绝对温度<BR>absorber 吸收器,过滤器,吸收管,减震器<BR>absorbite 活性碳,吸附器<BR>absorption吸收<BR>abulia 意识缺失<BR>abuse 违反操作规程,滥用<BR>acanthi 棘突,棘<BR>accentuation 增强,亢进<BR>access 存取,进口,入口<BR>accessory respiratory muscle 辅助呼吸肌<BR>accident hemorrhage 意外性出血<BR>accident ward 急诊室<BR>accidental dural puncture 意外性硬脊膜刺穿<BR>accidental extubation意外拔管<BR>accommodator 调节器<BR>accountant 计算装置<BR>accumulation 积蓄<BR>accumulator 蓄电池,存储器<BR>accuracy 准确度,精度<BR>aceology 药疗学<BR>acetone bodies 酮体<BR>acetylcholine乙酰胆碱<BR>acetylcholine esterase 乙酰胆碱酯酶<BR>acid 酸,酸的,酸性的<BR>acid baseequilibrium酸碱平衡<BR>acid-base balance 酸碱平衡<BR>acid-base equilibrium 酸碱平衡<BR>acid-intoxication 酸中毒<BR>acidemia酸血症<BR>acidosic 酸中毒的<BR>acidosis 酸中毒<BR>acidotic 酸中毒的<BR>acies 边缘,缘<BR>acinus renis 肾小球<BR>acmesthesia 针刺感觉<BR>acography 治疗记录<BR>acology 治疗学<BR>aconuresis 小便失禁<BR>acquired immunodeficiency syndrome(AIDS)<BR>获得性免疫缺陷综合症,艾滋病<BR>acratia 无力<BR>acraturesis 排尿无力<BR>acrinia 分泌缺乏<BR>acro-agnosis 肢体感缺失<BR>acro-anesthesia 四肢麻木<BR>acro-asphyxia 肢端缺氧<BR>acroaesthesia 感觉过敏,肢痛<BR>acrocheir 指尖<BR>acrocyanosis 手足发绀<BR>acropachy 杵状指<BR>acroparalysis 肢体瘫痪<BR>acroparesthesia 肢端感觉异常<BR>acrostealgia 肢端痛<BR>acroteric 末梢的,周围的<BR>action of arrest 阻止作用<BR>action potential 动作电位<BR>action-current 动作电流<BR>activate 活化,激活,致活<BR>activated state 激活状态<BR>actual 实际的,现实的<BR>acuesthesia 听觉<BR>acupuncture 针刺<BR>acupuncture anesthesia 针刺麻醉<BR>acupuncture anesthesia apparatus 针麻仪<BR>acute 急性的<BR>acute abdomen 急腹症<BR>acute abscess 急性脓肿<BR>acute anemia 急性贫血<BR>acutenaculum 持针器<BR>acute pain 急性疼痛<BR>addition 加,添加<BR>additive action 相加作用<BR>additive effect 相加作用<BR>ademonia 精神紧张,苦闷<BR>adenomammectomy 乳腺切除术<BR>adenopharyngitis 咽扁桃体炎<BR>adenophyma 淋巴结肿<BR>adherent 粘连的<BR>adhesiectomy 粘连切除术<BR>adhesive electrode 贴附电极<BR>adiabatic 绝热的<BR>adiaemorrhysis 血液循环停止<BR>adipose 肥胖的,脂肪的<BR>adiposis 肥胖症<BR>adiposis universalis 全身肥胖症<BR>adiposity 肥胖(症)<BR>aditus glottidis inferior 声门下口<BR>aditus glottidis superior 声门上口<BR>adjection 附加作用<BR>adjunction 附加(药物)<BR>adjustable oxygen density face mask 可调氧浓度面罩<BR>adjustable synchronous respirator 可控同步呼吸机<BR>administration 给予,投与,管理<BR>adrenalectomy 肾上腺切除术<BR>adsorbent 吸附剂<BR>adsorption 吸附作用<BR>adult respiratory distress syndrome (ARDS) 成人型呼吸窘迫综合症<BR>advanced life support (ALS) 后期复苏 <BR>adverse reaction 不良反应<BR>aeremia 气栓,气泡栓塞<BR>aero-emphysema 肺气肿<BR>aeroperitoneum 气腹<BR>aeropleura 气胸<BR>aerosol therapy 雾化疗法<BR>aerosolization 雾化给药 <BR>aesthema 感觉<BR>aesthesia 感觉<BR>aesthesis感觉<BR>agent 物质,药物,作用因子<BR>aging 老化,老龄化<BR>aglobulia红细胞减少<BR>aglobuliosis 红细胞减少<BR>agnogenic 原因不明的<BR>agomphiasis 无牙,缺牙,牙动<BR>agomphious 无牙的,缺牙的<BR>agomphosis无牙,缺牙,牙动<BR>agonal breathing 终末频死呼吸<BR>agonist 兴奋剂,激动剂<BR>air duct 通气道<BR>air embolism 空气栓塞<BR>air pressure gauge 空气压力表<BR>air-bag 气囊<BR>air-gun 喷雾器<BR>airway 气道,呼吸器<BR>airway control 气道保持通畅,气道控制<BR>airway obstruction 气道阻塞<BR>airway pressure 气道压<BR>airwayresistance 气道阻力<BR>airway stenosis 气道狭窄<BR>akromegaly 肢端巨大症<BR>alae nasi 鼻翼<BR>albedo retinae 视网膜水肿<BR>albumen 白蛋白<BR>albumin 白蛋白<BR>algaesthesis 痛觉<BR>alganesthesia 痛觉缺失<BR>algesia 痛觉<BR>algesic 疼痛的<BR>algogenesia 疼痛产生<BR>algogenesis 疼痛产生<BR>algospasm 痛性痉挛<BR>alkalemia 碱血症<BR>alkali 碱<BR>alkali reserve 碱储备,碱储量<BR>alkali-poisoning 碱中毒<BR>alkalosis 碱中毒<BR>alkalotic碱中毒的<BR>allergia 变应性,过敏性,变应反应<BR>allergic constitution 过敏体质,变态性体质<BR>allergic reaction 变态反应,过敏反应<BR>allolalia 言语障碍<BR>allomnesia 记忆障碍<BR>allophasis 语无伦次<BR>allophemy 语无伦次<BR>alloplasia 发育异常<BR>alveolar 肺泡的<BR>alveolar air 肺泡气<BR>alveolar gas 肺泡气<BR>alveolar gas exchange 肺泡气体交换<BR>alveolar hypoventilation 肺泡通气不足<BR>alveolar hypoxia 肺泡性缺氧<BR>alveolar ventilation 肺泡通气<BR>ambulance 急救车<BR>ambulatorium 门诊所,诊所<BR>aminofilina 氨茶碱<BR>aminophylline 氨茶碱<BR>amnesia 记忆缺失,遗忘(症)<BR>amnestic 遗忘的,引起遗忘的<BR>amnionic fluid embolism 羊水栓塞(症)<BR>amniotic embolism 羊水栓塞<BR>amyasthenia 肌无力<BR>amyasthenic 肌无力的<BR>anaemia 贫血<BR>analgesia 止痛<BR>analgesic 镇痛的,止痛药<BR>analgesic action 镇痛作用<BR>analgesist 麻醉医师<BR>analgetic 镇痛药,止痛的<BR>anapausis 催眠<BR>anapetia 血管扩张<BR>anaphylactic shock 过敏性休克<BR>anaphylaxis 过敏反应<BR>anaplasty 整形术<BR>anapnea 窒息解除<BR>anapnoea 窒息解除<BR>anastomosis 吻合术<BR>anatomical dead space 解剖死腔<BR>anatomy 解剖(学)<BR>ancon 肘<BR>anesthecinesia 感觉与运动能力缺失<BR>anesthesia 麻醉<BR>anesthesia by freezing 冷冻麻醉<BR>anesthesia chart 麻醉记录(用纸)<BR>anesthesia machine 麻醉机<BR>anesthesia record 麻醉记录<BR>anesthesia set 麻醉器械包<BR>anesthesiologist 麻醉学家<BR>anesthesiology 麻醉(科)学<BR>anesthesiophore 有麻醉作用的<BR>anesthetic action 麻醉作用<BR>anesthetic agent 麻醉药<BR>anesthetic apparatus 麻醉机<BR>anesthetic drug 麻醉药<BR>anesthetic equipment leakage 麻醉装置漏气<BR>anesthetic machine 麻醉机<BR>anesthetic pollution 麻醉药污染<BR>anesthetic potency麻醉效能<BR>anesthetic toxicity 麻醉药毒性<BR>angina epiglottidea 会厌炎<BR>angina laryngea 喉炎<BR>angina pectoris 心绞痛<BR>angio-edema 血管(神经)性水肿<BR>angiocardiography 心血管造影术<BR>angiocavernoma 海绵状血管瘤<BR>angiosclerosis 血管硬化<BR>angiospasm 血管痉挛<BR>angiospastic anemia 血管痉挛性贫血<BR>anonymous cartilage 环状软骨<BR>antagonism 拮抗<BR>antagonist 拮抗药,对抗肌<BR>antanacathartic 止吐药,止吐的<BR>antasthmatic 止喘的,止喘药<BR>antegrade amnesia 顺行性健忘(症)<BR>antemetic 止吐的,止吐剂<BR>anti-disturbance 抗干扰<BR>antianxiety drugs 抗焦虑药<BR>antibody 抗体<BR>antidote 解毒药<BR>antiemetic 止吐剂<BR>antiemetic drug 止吐药<BR>antihistamine drug 抗组胺药<BR>antihypertensive agent 降压药,抗高血压药物<BR>antihypertensive drug 降压药<BR>antinarcotic麻醉拮抗药<BR>antinauseant 止恶心药,抗恶心的<BR>antispasmodic 解痉药<BR>antispastic 解痉药<BR>anxiety 不安,苦闷<BR>anxiety state 焦虑状态<BR>anxiolytic 抗不安药,抗不安的<BR>anxiolytic agent 抗不安药,抗焦虑药<BR>anxiolytics 抗焦虑药<BR>aorta abdominalis 腹主动脉<BR>apnoea 呼吸暂停,窒息<BR>apparatus 装置,器具,器械<BR>appreciation 鉴定<BR>arachnoid 蛛网膜(的)<BR>arachnoid cavity 硬膜下腔<BR>araiocardia 心搏徐缓<BR>arrhythmia 心律不齐,心律失常,无节律<BR>arrhythmia respiratoria呼吸性心律不齐<BR>arousal reaction 唤醒反应<BR>arrest 停止<BR>arrhythmia 心律不齐<BR>arteria 动脉<BR>arteria axillaris 腋动脉<BR>arteria brachialis 肱动脉<BR>arteria carotis communis 颈总动脉<BR>arteria carotis externa 颈外动脉<BR>arteria carotis interna 颈内动脉<BR>arteria dorsalis pedis 足背动脉<BR>arteria femoralis 股动脉<BR>arteria radialis 桡动脉<BR>arteria subclavia 锁骨下动脉<BR>arteria ulnaris 尺动脉<BR>arteria vertebralis 椎动脉<BR>arterial catheter 动脉内置(插)管<BR>arterial embolism 动脉栓塞(症)<BR>arterial pressure transducer 动脉压换能器<BR>arterial transfusion 动脉输血(法)<BR>arteriopuncture 动脉穿刺<BR>arteriosclerosis 动脉硬化<BR>arteriospasm 动脉痉挛<BR>artificial 人工的<BR>artificial abortion 人工流产<BR>artificial blood vessel 人造血管<BR>artificial breathing 人工呼吸<BR>artificial circulation 人工循环<BR>artificial respiration 人工呼吸<BR>artificial teeth 假牙,义齿<BR>artificial ventilation 人工通气<BR>aspiration 吸引,误吸<BR>aspiration pneumonia 吸入性肺炎<BR>aspiration pneumonitis 吸入性局灶性肺炎<BR>aspirator 吸引器,吸引装置<BR>assist/control-mode ventilation (A/CMV) 辅助/控制通气<BR>asthma 支气管过敏,哮喘<BR>asthmatic attack 哮喘发作<BR>asthmatic crisis 哮喘危象<BR>asthmatoid wheeze 哮喘样喘鸣<BR>asthmatorthopnea 哮喘性端坐呼吸<BR>atrial fibrillation 心房颤动<BR>atrial flutter 心房扑动<BR>atrionector 窦房结<BR>atrioventricular heart-block 房室传导阻滞<BR>attack 发作<BR>auricular fibrillation心房纤颤<BR>auricular flutter 心房扑动<BR>autohemotransfusion 自体输血<BR>autotransfusion 自身输血<BR>awaken test 唤醒试验<BR>activated partial thromboplastin time(APTT) 活化部分凝血酶原时间<BR>alanine aminotransferase(ALT)丙氨氨基转移酶<BR>aspartate aminotransferase(AST) 天门冬酸氨基转移酶<BR>alkaline phosphatase(AKP) 碱性磷酸酶<BR>albumin白蛋白<BR>atrial hypertrophy心房肥大<BR>atrial premature beat房性早博<BR>atrial flutter心房扑动<BR>atrial fibrillation心房颤动<BR>anemia贫血<BR>auriculo-ventrivular block房室传导阻滞<BR>atelectasis肺不张<BR>angina心绞痛<BR>adult respiratory distress syndrome(ARDS) 成人呼吸窘迫综合征<BR>anterior-lateral decompression of spinal canal for vertebral fracture and dislocation脊柱骨折脱位椎管侧前方减压术<BR>amputation of forearm前臂截肢术<BR>arthrodesis of metacarpal joint of thumb拇指腕掌关节融合术<BR>arthroplasty of metacarpophalangeal joint掌指关节成形术<BR>amputation through thigh大腿截肢术<BR>amputation through leg小腿截肢术<BR>ankle athroplasty人工踝关节置换<BR>arthrodesis of ankle踝关节融合术<BR>ankylosis of temporomandibular joint颞下颌关节强直<BR>arthroplasty of temporomandibular joint颞下颌关节成形术<BR>adenolymphoma腺淋巴瘤<BR>adenoid cystic carcinoma腺样囊性癌<BR>ameloblastoma造釉细胞瘤<BR>aneurysm动脉瘤<BR>acquired arteriovenous fistula 后天性动静脉瘘<BR>accessory auricle副耳<BR>alar collapse鼻翼萎缩征<BR>acute abdomen急腹症<BR>appendicitis阑尾炎<BR>anal fistula肛瘘<BR>anal fissure肛裂<BR>acute pancreatitis急性胰腺炎<BR>adhesive intestinal obstruction粘连性肠梗阻<BR>appendicectomy阑尾切除术<BR>abdominoperineal resection of anus and rectum(Mile's operation) 直肠、肛管经腹会阴联合切除术<BR>arterial embolism动脉血栓<BR>arteriosclerotic vascular disease动脉硬化性血管病<BR>aorta-arteritis大动脉炎<BR>aortoiliac and aortofenoral bypass腹主动脉-髂动脉架桥术及腹主动脉-股动脉架桥术<BR>aortoiliac endarterectomy腹主动脉及髂内动脉内膜剥脱数<BR>B<BR>backward heart-failure 反向性心力衰竭<BR>balanced anesthesia 平衡麻醉<BR>basal anesthesia 基础麻醉<BR>basal metabolic rate 基础代谢率<BR>basal narcosis 基础麻醉<BR>basic life support (BLS) 初期复苏,基本生命支持<BR>basis anesthesia 基础麻醉<BR>bathypnea 深呼吸<BR>bigemina 二联律<BR>bigeminy 二联律<BR>bleeding tendency 出血倾向<BR>blepharedema 眼睑水肿<BR>blepharoedema 眼睑水肿<BR>blepharoptosis 眼睑下垂<BR>blind intubation 盲探插管<BR>blind nasotracheal intubation 经鼻盲探插管术<BR>block 阻滞,阻断<BR>block anesthesia 阻滞麻醉<BR>blockage 阻滞,阻塞,阻断<BR>blocking 阻断<BR>blocking agent 阻断剂,阻滞剂,阻抑剂<BR>blood donation 供血<BR>blood donor 供血者<BR>blood fat 血脂<BR>blood gas 血气<BR>blood gas analyzer 血气分析仪<BR>blood group 血型<BR>blood preparation 血液制剂<BR>blood recipient 受血者<BR>blood sample 血样<BR>blood sugar 血糖<BR>blood supply 血液供给<BR>blood transfusion 输血<BR>bloodtransfusion apparatus 输血器<BR>blood transfusion reaction 输血反应<BR>blood-brain barrier 血脑屏障<BR>blood-cerebrospinal barrier 血-脑屏障<BR>bloody urine 血尿<BR>blood volume 血容量<BR>body 体,身体<BR>body fluid 体液<BR>body height 身高<BR>body position 体位<BR>body posture 体位<BR>body surface aren 体表面积 <BR>body weight 体重<BR>bolus dose 单次剂量<BR>brachial plexus block 臂丛阻滞<BR>brachial plexus block by axillary route 腋窝法臂丛神经阻滞<BR>brachial plexus block by interscalene route 斜角肌间法臂丛神经阻滞<BR>brachial plexus block by subclavicular route 经锁骨下路臂丛神经阻滞<BR>brachial plexus block by supraclavicular route 锁骨上法臂丛神经阻滞<BR>brachial plexus paralysis 臂丛神经麻痹<BR>brachiplex臂丛<BR>brachycardia 心动过缓<BR>breast bone 胸骨<BR>breast-pang 心绞痛<BR>breath analyzer 呼吸气体分析仪<BR>breathing-holding 吸气屏气<BR>breat h holding test (Sebarese’s test) 屏气试验<BR>breathing circle system 呼吸环路系统<BR>bronchial catheter with double tubes 双腔支气管导管<BR>bronchial spasm 支气管痉挛<BR>bronchiospasm 支气管痉挛<BR>bronchodilator 支气管扩张药<BR>bronchofiberscope 纤维支气管镜<BR>bucking 呛咳<BR>bundle branch block 束支传导阻滞<BR>burn 烧伤<BR>blood platelets count(BPC) 血小板计数<BR>blood uria nitrogen(BUN) 血清尿素氮<BR>blood sugar血糖<BR>bundle branch block束支传导阻滞<BR>bronchitis支气管炎<BR>bronchiectasis支气管扩张<BR>bronchial asthma支气管哮喘<BR>breath holding test屏气试验<BR>Boyd’samputation Boyd 截肢术<BR>benign tumor良性肿瘤<BR>branchial cleft cyst鳃裂囊肿<BR>bacterial liver abscess细菌性肝脓肿<BR>bile duct tumor胆管肿瘤<BR>bypass operation for intestinal obstruction肠梗阻捷径手术<BR>biliary enterostomy胆肠内引流术<BR>Buerger discase血栓闭塞性脉管炎<BR>bypass with reversed autogenous long saphenous vein自体大隐静脉导致转流术<BR>C<BR>capillary 毛细血管的<BR>capillary bed毛细血管床<BR>capillary bleeding 毛细血管出血<BR>capillary fragility 毛细血管脆性<BR>carbon dioxide combining power 二氧化碳结合力<BR>carbon dioxide retention 二氧化碳蓄积<BR>cardiac arrest 心脏停搏<BR>cardiac death 心脏猝死<BR>cardiac decompensation 心代偿失调<BR>cardiac defibrillator 心脏除颤器<BR>cardiac depressant 心脏抑制剂<BR>cardiac depression 心脏抑制<BR>cardiac dyspnea 心原性呼吸困难<BR>cardiac edema 心原性水肿<BR>cardiac index (CI) 心脏指数<BR>cardiac insufficiency 心功能不全<BR>cardiac massage 心脏按摩(压)<BR>cardiac output (CO) 心排出量<BR>cardiac reserve 心脏储备力<BR>cardiopulmonary cerebral resuscitation (CPCR) 心肺脑复苏<BR>cardiopulmonary resuscitation (CPR) 心肺复苏<BR>carina 隆突<BR>cartilage 软骨<BR>cartilago arytaenoidea 勺状软骨<BR>cartilago cricoidea 环状软骨<BR>cartilago gutturalis勺状软骨<BR>cartilago peltata 甲状软骨<BR>cauda equina syndrome 马尾综合症<BR>caudal anesthesia 骶管麻醉<BR>caudal block 骶管阻滞<BR>cavum epidurale 硬膜外腔<BR>cavum subarachnoidale 蛛网膜下腔<BR>cavum subdurale 硬膜下腔<BR>cavum thoracis 胸腔<BR>central venous pressure (CVP)中心静脉压<BR>cerebral edema 脑水肿<BR>cerebrospinal fluid(CSF)脑脊液<BR>cerebral resuscitation 脑复苏<BR>cerebrovascular accident 脑血管意外<BR>cervical plexus block 颈神经丛阻滞<BR>cervical vertebra 颈椎<BR>cervicobrachial pain 颈臂痛<BR>chemosis球结膜水肿<BR>chill 寒战,受寒<BR>choloplania 黄疸<BR>chondralgia软骨痛<BR>chromaffin cells 嗜铬细胞<BR>chronic pain 慢性疼痛<BR>classification 分类<BR>clavicle锁骨<BR>clavicular 锁骨的<BR>cleftpalate 腭裂<BR>clinical analysis 临床分析<BR>clinography 临床记录<BR>close system 紧闭装置<BR>closed chest cardiac compression 胸外心脏按压<BR>CO2 absorbent 二氧化碳吸收剂<BR>CO2 acummulation 二氧化碳蓄积<BR>collarbone 锁骨<BR>colloid 胶体<BR>colloid oncotic pressure 胶体渗透压<BR>colloid osmotic pressure 胶体渗透压<BR>colloid solution 胶体溶液<BR>colloidal 胶体的<BR>coma position 昏迷状态<BR>combination 结合,复合<BR>combined anesthesia 复合麻醉<BR>competitive 竞争的<BR>competitive agent 竞争性药物<BR>competitive drug 竞争性药物<BR>component transfusion 成分输血<BR>congenital 先天的<BR>congestive heart failure 充血性心力衰竭<BR>conscious intubation 清醒插管术<BR>contamination 污染<BR>continuous epidural anesthesia 持续硬膜外麻醉<BR>continuous intravenous infusion 持续静脉输入<BR>continuous positive pressure breathing 持续正压呼吸(法)<BR>continuous positive pressure ventilation持续正压通气<BR>continuous spinal anesthesia 持续脊髓麻醉<BR>controlled hypotension 控制性降压<BR>controlled respiration 控制呼吸<BR>control-mode ventilation (CMV)控制通气<BR>corectasis 瞳孔散大<BR>corediastasis 瞳孔散大<BR>costal cartilage 肋软骨<BR>cough 咳嗽<BR>cough reflex 咳嗽反射<BR>cranial bone 颅骨<BR>craniocerebral 颅脑的<BR>crico-esophageal compress 环-食管压迫手法<BR>cricoid cartilage 环状软骨<BR>cricoid pressure 环状软骨压迫(法)<BR>cricothyroid membrane 环甲膜<BR>cricothyrotomy 环甲膜切开(术)<BR>crisis 危像<BR>critical 危重的,临界的<BR>critical care medicine 急救医学,危重医学<BR>crowing convulsion 喘鸣性喉痉挛<BR>cruenturesis 血尿<BR>crush syndrome 挤压综合症<BR>cumulative 蓄积的<BR>creatinine(Cr) 血清肌酐<BR>cardiac function心功能<BR>coronary heart disease 冠心病<BR>congenital heart disease先天性心脏病<BR>cardiomyopathy心肌病<BR>chronic pulmonary heart disease慢性肺源性心脏病<BR>cirrhosis of liver肝硬化<BR>cerebral hemorrhage脑出血<BR>cerebral infarction脑梗塞<BR>coma昏迷<BR>corrective operation of scoliosis and kyphosis脊柱侧突及后凸畸形矫形术<BR>curettage and excision with bone grafting for enchondroma软骨瘤刮除与切除<BR>close reduction and internal fixation by compressive screws for femoral neck fracture股骨颈骨折闭合复位加压螺纹钉内固定术<BR>Condylar fracture髁突骨折<BR>Capillary hemangioma毛细管型血管瘤<BR>Cavernous hemangioma海绵状血管瘤<BR>Curettage of cyst囊肿刮除术<BR>carcinoma of tongue舌癌<BR>Carcinoma of check 颊癌<BR>Carcinoma of gingival牙龈癌<BR>Carcinoma of mouth floor口底癌<BR>Carcinoma of lip唇癌<BR>Carcinoma of maxillary sinus上颌窦癌<BR>Combined dissection of craniofacial颅颌联合根治术<BR>Combined dissection of tongue ,。
解淀粉芽孢杆菌抑菌作用及在养猪业中的应用
解淀粉芽孢杆菌抑菌作用及在养猪业中的应用唐文杰;余冰;虞洁;陈代文【摘要】With the rapid development of pig industry, intestinal health issues of pigs have drawn much atten?tion. Pathogenic microbial infections and various stresses cause diarrhea, intestinal dysfunction and even death in pigs. These problems can be alleviated by using nutrition regulators such as probiotics. In previous studies, a variety of effective antibiotic substances were isolated and purified from Bacillus amyloliquefaciens, and the compositional structure of them was clarified, which provided a theoretical basis for further elucidating the anti?bacterial abilities of Bacillus amyloliquefaciens against bacteria and fungi. In this review, the antibacterial mechanism of Bacillus amyloliquefaciens is introduced, and its application in pig industry is reviewed in order to provide reference for development of the application of Bacillus amyloliquefaciens as a probiotics.[ Chinese Journal of Animal Nutrition, 2019, 31(6) :2502?2506]%随着生猪产业的快速发展,肠道健康问题备受关注.病原微生物感染和各种应激造成猪腹泻、肠道功能紊乱,甚至导致猪死亡.通过使用微生态制剂等营养调控因子可以缓解这些问题.在前人的研究中,从解淀粉芽孢杆菌中分离纯化了多种有效抑菌物质,并明确了其中部分物质的组成结构,为进一步阐明解淀粉芽孢杆菌对细菌和真菌抑制能力提供了理论基础.本文结合解淀粉芽孢杆菌抑菌机理,对其在养猪业中的应用情况进行综述,为开发解淀粉芽孢杆菌作为益生素的应用价值提供参考.【期刊名称】《动物营养学报》【年(卷),期】2019(031)006【总页数】5页(P2502-2506)【关键词】解淀粉芽孢杆菌;养猪业;益生菌;应用【作者】唐文杰;余冰;虞洁;陈代文【作者单位】四川农业大学动物营养研究所,动物抗病营养教育部重点实验室,雅安625014;四川农业大学动物营养研究所,动物抗病营养教育部重点实验室,雅安625014;四川农业大学动物营养研究所,动物抗病营养教育部重点实验室,雅安625014;四川农业大学动物营养研究所,动物抗病营养教育部重点实验室,雅安625014【正文语种】中文【中图分类】S816.7;S828前人研究结果表明,肠道菌群对胃肠道屏障功能、胃肠道发育、肠道神经系统功能和肠道免疫功能等诸多方面产生重要的影响[1-5]。
小儿腹泻(英文)
12
Rotavirus
13
The major cause of death among world’s
children and the number one killer of children
under five in many developing countries.
2
Disease Burden
Worldwide 3-5 billion episodes/year 4-5 million deaths/year
INFANTILE DIARRHEA
CHCUMS
DIVISION OF INFECTIOUS DISEASE AND GASTROENTEROLOGY
1
Background
Diarrhea is a clinical syndrome of diverse
etiology associated with many influencing factors. It is the most frequent childhood disease second only to the respiratory infection.
Babies on solids: thicken and darken slightly have a stronger odor
5
Why diarrhea is more dangerous for children ?
人畜共患传染病的防治
(7) 韩国出血热 (Korean hemorrhagic fever) 。①传染 媒介动物:大鼠。②临床症状:肌痛、头痛、咳嗽。③ 传染途径:吸入感染、啮齿类动物咬伤、伤口污染。 (8) 淋巴结性脉络丛脑膜炎病毒感染症 (L,ymphocytic choriomeningitis virus infection)。①传染媒介动物: 小鼠、仓鼠。②临床症状:类似流行性感冒症状,但有 头痛、肌肉痛、发热、恶心、呕吐、喉痛、畏光。有时 亦见发疹、下痢、咳嗽、瞻望。容易被误认为流行性感 冒、疱疹性脑炎或结核性脑炎。③接触感染,接触小鼠 粪便和尿液、吸入受污染的灰尘、咬伤。 (9)狂犬病(Rabies)。①传染媒介动物:所有哺乳类。② 临床症状:头痛、肌痛、发热、抽搐、昏厥。③传染途 径:咬伤、皮肤伤口或黏膜感染含狂犬病毒的唾液。
(3) 宠物爱好者要学习一些有关人畜共患疾病的知识, 定期让宠物进行某些疾病的预防接种。
(4) 同时要意识到与宠物拥抱、亲吻或者同桌吃饭、同 床就寝等过分亲热的行为都是不卫生和有害的。 (5) 在被怀疑患狂犬病的动物咬伤时,要立即求医救治。 (6) 饮食上要讲究卫生,选用经过检验的乳、肉、蛋等 食品,并提倡熟食。 专家建议,相对于个体的自我防护,更为重要的是建立 全国性乃至全球性的防疫体系,对各种人畜共患病进行 控制,做到早发现、早报告、早处理,严防某些疾病的 暴发和越境传播。这样,才能将人畜共患病带来的损失 降到最低,并防止由此带来更大的灾难。
(4) 卡氏肺囊虫症 (Pneumocystosis) 。①传染媒介动物: 大鼠、小鼠、兔。②症状,发热、咳嗽、呼吸困难、导 致窒息。⑨传染途径:经胎盘感染胎儿。
六、人畜共患疾病:实验动物蠕虫感染疾病
食品安全有关的英文PPT大纲
Refers to foreign objects such as glass, metal fragments, dirt, and other debris that can contain food during production, processing, or storage
Regulatory Frameworks
Many countries have developed their own regulatory frameworks to ensure food safety, including laws, regulations, and inspection systems
01
Introduction to Food Safety
Definition and Importance
Definition
Food safety refers to the conditions and practices that ensure the safety of food from production to consumption, preventing foodborne illnesses and protecting consumer health
The presentation will cover the fundamental concepts of food safety, as well as discussions strategies for prevention and responding to food safety incidents Additionally, it will highlight the role of different stakeholders in ensuring food safety
21世纪大学英语应用型综合教程2U1译文
3. 不管是在发达国家,还是在发展中国家,食源
性疾病都是一个普遍且不断恶化的公共健康问题。
Unit 1: Text A
4. The global incidence of foodborne disease is difficult to estimate, but it has been reported that in 2005 alone 1.8 million people died from diarrheal diseases. A great proportion of these cases can be attributed to contamination of food and drinking water. Additionally, diarrhea is a major cause of malnutrition in infants and young children.
9. 食物污染给社区以及医疗系统造
成了巨大的社会和经济负担。1991 年在秘鲁再次爆发的霍乱致使那年 的鱼类和渔业产品出口损失达5亿美 元。
Unit 1: Text A
10-1. The safety of food derived from biotechnology needs to be carefully assessed. To provide the scientific basis for decisions regarding human health, new methods and policies to assess such food need to be developed and agreed upon internationally. The assessment should consider health benefits as well as possible negative health implications.
急性胃肠炎病历范文
急性胃肠炎病历范文英文回答:I recently had a case of acute gastroenteritis in my medical practice. The patient, a 35-year-old male, came to me complaining of severe abdominal pain, nausea, vomiting, and diarrhea. Upon further inquiry, he revealed that he had eaten at a local fast food restaurant the previous night.Upon physical examination, the patient appeared pale and dehydrated. His vital signs were stable, with aslightly elevated temperature. Abdominal examination revealed tenderness in the lower quadrants. Based on the patient's symptoms and history, I suspected a case of acute gastroenteritis.To confirm the diagnosis, I ordered a stool sample analysis. The results showed the presence of white blood cells and increased levels of fecal leukocytes, indicating an inflammatory response in the gastrointestinal tract.Additionally, the stool culture revealed the presence of Campylobacter jejuni, a common bacterial cause of gastroenteritis.Treatment for acute gastroenteritis typically involves supportive care, as the condition is usually self-limiting.I advised the patient to maintain hydration by drinking plenty of fluids and recommended an oral rehydration solution to replace lost electrolytes. I also prescribed an antiemetic to relieve his nausea and vomiting.In addition to symptomatic treatment, I educated the patient about proper hand hygiene and food safety practices to prevent the spread of the infection. I emphasized the importance of washing hands thoroughly with soap and water before handling food and after using the toilet. I also advised him to avoid consuming undercooked or contaminated food.The patient's symptoms gradually improved over the next few days, and he reported a decrease in abdominal pain, vomiting, and diarrhea. He followed the prescribedtreatment plan and made sure to practice good hygiene and food safety measures. After a week, he made a full recovery and returned to his normal activities.中文回答:最近在我的医疗实践中遇到了一例急性胃肠炎的病例。
留学生英语 周围神经peripheral nerve
2. axon degeneration
Distal degenerated inexcitable electrically.
nerve
is
Regeneration can occur since the basement membrane of the Schwann cell survives and act as a skeleton along which tha axon regrows up to a rate of about 1mm per day.
Pathological processes
Cause: damage of cell body,axon, myelin sheath, connective tissue, blood supply Three basic processes 1. Wallerian degeneration 2. Axon degeneration 3. Demyelination
Peripheral Nerve System
Neurology Department
Introduction
Anatomy
Peripheral nerves are made up of axon endoneurium Connective tissue perineurium epineurium Nerve trunks myelinated fibre unmyelinated fibre Myelin, protein-lipid complex function, insulating layer increase conduction rate
Motor symptoms:
7种不安全食物女人慎吃
7种不安全食物女人慎吃我们看电视、看报纸等等可以知道,每年都有许多人因为食品问题染病甚至去世,其中大多数人是因为吃水果、蔬菜、烤鸡或凉菜。
这都是因为什么呢?下文我们为大家列出七种食品,在食用时一定要慎重。
关爱自己的生命。
1、寿司危险因素:寿司的最大问题是寄生虫、扁形虫和蛔虫,例如生鱼中的寄生虫。
虽然生鱼不能保证安全,但是,蘸酱汁或者青芥可能会起到轻微的杀菌作用。
解决办法:鱼至少在145度的高温下烹调1分钟,可杀死鱼中的任何寄生虫。
但是,那就不是寿司了。
唯一可生吃鱼又保证不携带寄生虫的方法是吃用冷冻鱼做成的寿司。
美国食品药品管理局推荐,在零下31度的温度下冷冻鱼至少15小时可杀死寄生虫。
2、鸡蛋危险因素:感染因子是在鸡蛋里面,唯一根除细菌的方法就是将鸡蛋煮熟。
解决办法:不吃生鸡蛋和半熟的鸡蛋。
蛋黄未凝固的鸡蛋有潜在的危险。
为了安全,你最好吃煮老一点的鸡蛋或固体状的鸡蛋。
高温会杀死任何可能存在的细菌,你可放心吃水煮鸡蛋或者两面煎蛋。
3、牛肉馅危险因素:吃生牛肉或者半熟牛肉都不利于健康。
牛肉可能携带沙门氏菌或者大肠杆菌。
牛肉馅比牛排更危险,因为它被用手握的可能性更大,绞成肉馅后,它的表面更大,藏匿细菌更多。
解决办法:唯一能保证无菌的方法是购买那些经过杀菌处理的牛肉。
4、包装好的绿色蔬菜危险因素:包括莴苣和菠菜在内的叶状绿色蔬菜一直是近年来几种疾病暴发的“罪魁祸首”。
其中规模最大的疾病暴发之一是2006年的大肠杆菌暴发,与成包的菠菜有关,导致199人患病,3人死亡。
大肠杆菌和沙门氏菌感染农产品的方法多样,动物粪便渗透到水中或者土壤中,或者手工采摘或者包装过程中传染。
大多数情况下,水并不能洗掉这些危险。
解决办法:卷心菜外面的叶子更可能被污染,因此,摘掉叶子,洗手,然后再准备其余的部分。
5、芽菜危险因素:芽菜生长的环境最利于有害细菌的滋生。
解决办法:唯一能保证安全的方法是烹调。
专家建议将芽菜投入汤锅或大火煸炒。
幽门螺杆菌说明书A3版
【产品性能指标】
1.性能特点
从 207 名有症状和无症状试验对象中采集临床试
样。试验对象均经内窥镜检查。年龄从 19 到 83
岁,平均年龄 52 岁。通过对比试验,评估BioSign®
H. pylori WB与活组织检查/组织学方法、凝集法和
酶联免疫法检测抗幽门螺旋杆菌的性能特点。以
下各表总结了试验结果。
【主要组成成分】 A.主要组成成分 1.测试板条:由纤维膜、染色垫组成,纤维膜上包 被有幽门螺旋杆菌抗原、抗鼠 IgG 抗体;染色垫 上包被有胶体金偶联的幽门螺旋杆菌抗原、胶体 金偶联的抗人 IgG 抗体。 2.显影液:其成分为磷酸钠缓冲液。 3.产品说明书 B.需要但未提供的材料 1.血清或血浆收集用的采血管 2.血浆抗凝剂(如 CPDA-1,肝素,或 EDTA) 3.离心机 4.微量吸管(0-200ul 量程) 5.毛细管 6.柳叶刀 C.警告和注意事项 1.仅供体外诊断使用 2.不同批号的产品,不能互换使用,不要使用已 过期的产品。 3.每次采集新的样本时,请更换毛细管。不能用口 吹吸毛细管。 4.不能在样本或试剂盒操作区域内吸烟、吃东西、 喝水。 5.操作样本或试剂时请使用一次性手套,试验完成 后请认真洗手。 6.所有患者样本按照具有潜在传染性疾病类物质 处理规定的要求进行。在整个操作过程中应仔细 观察,按照样本处理的标准操作规程进行试验, 避免微生物感染风险。 7.本试剂盒中所包括的显影液中含有保护剂叠氮 化钠,叠氮化钠可与铅或铜叠氮化钠会与铅和铜 类管路反应,可能会形成爆炸性金属叠氮化合物。 丢弃至水池后,应用大量的水进行冲洗,以免造 成叠氮化物的堆积。 8.在使用前,应保证抗幽门螺旋杆菌 IgG 抗体检 测试剂盒贮存于原包装密封袋内。请不要使用密 封袋已破损的产品。
幽门螺杆菌感染
幽门螺杆菌感染本刊的这一栏目首先提供一份强调某一常见临床问题的病例摘要,然后提出支持各种策略的证据。
如果有正式指南,作者接下来会对其进行综述。
文章以作者的临床建议结尾。
一名来自东欧的32岁女性移民因持续性上腹痛和腹胀接受检查。
之前的检查显示,全血细胞计数和全面的代谢检查结果正常,乳糜泻血清学检查结果呈阴性。
幽门螺旋杆菌IgG血清检测结果呈阳性。
患者接受了为期10日的每日2次,每次20 mg奥美拉唑、1 g阿莫西林和500 mg克拉霉素治疗,但症状持续存在。
您将如何进一步检查和治疗该患者?临床问题幽门螺旋杆菌感染是全球范围内均可见到的一种常见且通常持续终生的感染1。
研究提示,不同地区的感染率不同,但由于人口增长,以及再次感染和因根除不成功导致的复发,感染者数量在过去30年中保持稳定,甚至有所增加2。
较差的社会经济状况是幽门螺杆菌感染的危险因素2,因为较差的社会经济状况与较拥挤的居住条件相关,而拥挤的居住条件有利于幽门螺杆菌的家庭内传播3。
此外还有内镜检查导致的医源性感染4。
虽然大多数感染者无症状,但我们已经发现幽门螺杆菌感染与数种疾病直接相关,尤其是消化性溃疡病和非溃疡性消化不良。
已经有证据(在下文中综述)表明,通过治疗根除幽门螺杆菌可降低这两种疾病的风险5-7,但其中有关非溃疡性消化不良的数据不太统一。
胃癌也与感染幽门螺杆菌密切相关。
日本的一项研究表明,在感染幽门螺杆菌的消化性溃疡、消化不良或胃不典型增生患者中,有2.9%发生了胃癌(7.8年的平均随访期间),而在未感染幽门螺杆菌的上述疾病患者中未发现胃癌8。
根据强有力的证据,世界卫生组织(WHO)已将幽门螺杆菌归类为导致胃腺癌的1类致癌物9,10。
除日本之外,因幽门螺杆菌感染导致胃癌发病率增加的区域包括中东、东南亚、地中海地区、东欧、中美洲和南美洲。
在世界上幽门螺杆菌感染率高的地区(例如东欧和东亚)长大,如今居住在美国或西欧的移民患胃癌的风险也增加。
引起牛瘤胃酸中毒的两种疾病及诊治
2022年第11期牛瘤胃酸中毒是牛的一种常见多发病,病发原因是瘤胃内容物中乳酸含量过多,且pH 降低到5.0以下,引发的较为严重的牛瘤胃功能障碍。
该病如果得不到及时有效的处理,会因为消化障碍使牛的营养摄取不足,致使牛陷入虚弱状态,严重时会导致牛死亡。
本文针对容易引发牛瘤胃酸中毒的食道沟反射失败、牛瘤胃角化不全的防治方案进行了探讨,供参考。
1食道沟反射失败食道沟反射失败是诱发牛瘤胃酸中毒的一种常见病因,是一种原发慢性疾病,该种病症的急性型常见于新生的犊牛群体且通常都会伴随有一定的继发性并发症,以新生阶段犊牛的腹泻为主要表现,经人工饲养的羔羊也可出现这类疾病。
(1)食道沟是指从牛的贲门直到网胃—瓣胃孔部分,食道沟正确闭合才能使牛奶或其他替代物直接进入牛的真胃中。
食道沟反射失败就是牛的食道沟出现了部分闭合或闭合完全失败,此时,牛奶或其替代物就会进入到牛的网胃中,经过一系列的生理发酵之后产生乳酸或短链脂肪酸。
此后,牛瘤胃的内容物pH 值会短暂下降到4.0以引起牛瘤胃酸中毒的两种疾病及诊治王海明(青海省互助土族自治县五峰镇畜牧兽医站,青海互助810599)DOI:10.3969/J.ISSN.1671-6027.2022.11.050作者简介:王海明(1977~),女,青海互助人,兽医师,本科学历,研究方向:兽医。
摘要:牛瘤胃酸中毒是一种较为常见的疾病,对牛的生长发育会造成极大的影响,严重时会导致牛的死亡。
食道沟反射失败及牛瘤胃角化不全是引发牛瘤胃酸中毒的两种常见病症,本文分别基于两种疾病的发病原因、临床诊断分析,提出了与之相对应的防治方案。
关键词:牛瘤胃酸中毒;病因;诊断;防治方案沙门氏菌病有着反复性发作的特点,对牛羊疾病的治疗会造成一定困难。
养殖场应当做好牛羊幼崽的疫苗接种。
兽医选择土霉素注射液,剂量为10~30mg/kg.bw ,2次/d 。
也可按同样剂量口服土霉素片。
经过2~3d 治疗之后,可取得一定效果。
Unit1-Food Safety and Foodborne Illness
Unit 1: Warm up
Directions: You will hear a passage and you are required to fill in the blanks with the exact words you have just heard.
Food safety is considered to be an important public health issue
foodborne diseases each year has increased rapidly. Moreover,
developing countries bear the main impact of the problem due to the 4. ________ of a wide range of foodborne diseases. The global
Unit 1: Warm up
incidence(发生率) of foodborne disease is difficult to 5. estimate _______. While most foodborne diseases are occasional and often not reported, outbreaks may take on massive proportions(分 foodborne disease 6. ________ derived from 额 , 比 例 ). What’s more, the safety of food 7. ___________ assessed Other biotechnology(生物技术) needs to be carefully 8. ________. addressed to help ensure food safety, challenges, which need to 9. be _____________ include the globalization of trade in food, urbanization( 城市化 ), changes in lifestyles, international travel, environmental pollution, 10. deliberate ________ contamination(污染) and natural and manmade disasters.
细菌中多聚磷酸体的降解
细菌中多聚磷酸体的降解介绍细菌是一类微生物,它们在自然界中无处不在。
其中,一些细菌具有多聚磷酸体,这是一种储存磷的细胞器。
多聚磷酸体在细菌的生存和代谢中起着重要的作用。
本文将探讨细菌中多聚磷酸体的降解过程及其机制。
多聚磷酸体的结构和功能1.多聚磷酸体是一种由磷酸盐分子组成的颗粒状结构,存在于细菌的细胞内。
2.它们储存着大量的磷酸盐,供细菌在特定环境下使用。
3.多聚磷酸体还可以在细菌的生长和分裂过程中发挥调控作用。
多聚磷酸体的降解过程刺激信号的产生1.当细菌处于低磷环境中时,其细胞内的一些酶会被激活,开始降解多聚磷酸体。
2.这些酶的激活是通过一系列信号传导途径实现的,包括细菌内切换蛋白(Switch Protein)的作用。
酶的催化作用1.在多聚磷酸体降解过程中,一些特定的酶起到关键的催化作用。
2.例如,聚磷酸酶能够将多聚磷酸体中的磷酸盐水解为单个的磷酸分子。
降解产物的利用1.在多聚磷酸体降解过程中产生的磷酸盐可以被细菌再利用。
2.磷酸盐可以作为ATP(三磷酸腺苷)的合成前体,提供能量给细菌进行代谢活动。
多聚磷酸体降解的调控机制调控信号的产生和感知1.细菌在低磷环境中会产生一些特定的信号分子,如一磷酸腺苷(ppGpp)和二磷酸腺苷(ppGpp)。
2.这些信号分子能够调控多聚磷酸体的降解过程。
转录因子的调节1.转录因子是一类能够调节基因表达的蛋白质。
2.在细菌中,一些转录因子能够与多聚磷酸体结合,从而调控多聚磷酸体降解相关基因的表达。
基因表达的调整1.多聚磷酸体降解过程中,一些关键的酶和调控蛋白的基因会被启动或抑制。
2.这些基因的表达调整使细菌能够适应环境的变化并进行必要的代谢调节。
多聚磷酸体降解与细菌适应环境的关系1.多聚磷酸体降解使细菌能够利用储存的磷酸盐为能源,从而适应低磷环境。
2.细菌在低磷环境中的存活和繁殖依赖于多聚磷酸体降解的能力。
结论细菌中多聚磷酸体的降解是一个复杂而精密的过程。
它涉及到多个信号传导途径和调控机制。
Caninedistemperi...
Canine distemper in Siberian tiger cubs from Zagreb ZOO: case reportDean Konjević1, Ruža Sabočanec1, Željko Grabarević1, Andreas Zurbriggen2, Ingeborg Bata3, Ana Beck1, Andrea Gudan Kurilj1, Denis Cvitković11Veterinary Faculty, University of Zagreb, Croatia2Vetsuisse Faculty, University of Bern, Switzerland3Zagreb ZOO, CroatiaReceived June 5, 2009Accepted September 21, 2010AbstractCanine distemper is a contagious, potentially lethal disease of mainly domestic and wild canids,but also of many other mammalian species including large felids. In February 2004, two Siberiantiger (Panthera tigris altaica) cubs at the age of six months died at the Zagreb ZOO. The animalswere presented for necropsy with two days history of severe digestive disorders, characterizedmainly by haemathemesis. Dissections revealed catarrhal to pseudomembranous gastroenteritis(depending on the animal) accompanied with haemorrhagic oedema of the lungs. Necrotictonsillitis and disseminated depletion of the lymphocytes were the most prominent histologicalfindings in both examined animals, while intranuclear and intracytoplasmatic inclusion bodieswere found in the samples of the tongues and intestines. Representative portions of the livers,intestines, tonsils and lymph nodes were submitted for bacteriological and mycological analysis.The presence of Clostridium spp., Campylobacter coli and Escherichia coli was detected in gutsamples, coli-like bacteria were found in samples of liver, tonsils and lymph nodes, while Candidasp. was found in the gut and pharynx samples. Toxicological analysis excluded anticoagulant andorganophosphorous intoxication as the cause of death. Immunohistochemical analysis was positivefor canine distemper virus. Based on all this, epizootiological, clinical and additional findings,canine distemper was recognized as the cause of the observed condition in these animals.Large felids, digestive disorders, virus, immunohistochemistryCanine distemper (CD) is a worldwide infectious disease of mainly domestic dogs, but also of a broad spectrum of other species including large felids (Deem et al. 2000). The disease is caused by a negative-stranded morbilivirus of the Paramyxoviridae family that is closely related to the measles and phocine distemper virus. Despite the fact that CD is probably one of the best examples of a disease that has proved capable of compromising the conservation of several wild carnivore species (i.e. Williams et al. 1988; Roelke-Parker et al. 1996; Barret 1999; Kennedy et al. 2000; van de Bildt et al. 2002), it has been repeatedly found that canine distemper virus (CDV) historically is not pathogenic in lions and tigers. This hypothesis was tested by Myers et al. (1997) who examined 42 cases of large cat mortalities in Switzerland and found evidence that 19 samples were positive (the oldest positive sample originated from 1972), indicating that CDV infections in lions and tigers are older and more widespread than previously thought. In the present report we describe clinical, pathological, histological and immunohistochemical findings in a case of naturally occurring canine distemper in captive Siberian tiger cubs.Case report and findingsDuring February 2004, zoo-keepers reported that 2 out of 3 Siberian tiger (Panthera tigris altaica) cubs at the age of 6 months were exhibiting signs of gastrointestinal disorders. The cubs were immediately separated from their mother and the third cub. Their condition progressively deteriorated, with haemathemesis as the most prominent clinical symptom. The observed clinical condition was preliminary diagnosed as anticoagulant intoxicationACTA VET. BRNO 2011, 80: 047–050; doi:10.2754/avb201180010047 Address for correspondence:MVDr. Dean Konjević, Ph.D, Dipl. ECZM (Wildlife Population Health) University of Zagreb, Veterinary FacultyHeinzelova 55, 10 000 Zagreb, Croatia Phone: +385 1 2390 156E-mail:******************** http://www.vfu.cz/acta-vet/actavet.htmand prescribed therapy included vitamin K1 (Konakion®, Roche, Switzerland), H2 agonistto prevent gastric ulcers (Peptoran®, Pliva, Croatia) and trimethoprim-sulphadiazine combination (Trimetosul®48%, Pliva, Croatia) as supportive antibacterial therapy. Despite the therapy, one cub died 2 days after the onset of clinical signs, and the other survived for 2 more days. The third cub that remained with the mother exhibited no signs of disease and both of them received a 5-day full therapy. Necropsies revealed ulcerative pharyngitis and tonsillitis, and catarrhal to pseudomembranous gastroenteritis (depending on the animal) accompanied with haemorrhagic oedema of the lungs. Multifocal necroses were found on the liver and pancreas. Along with microscopic lesions underlying the described gross changes, necrotic tonsillitis and disseminated depletion of lymphocytes were the most prominent findings in both examined animals. Intracytoplasmatic and intranuclear inclusion bodies were recognized in the tongue and intestines (Plate III, Fig. 1). Representative portions of the liver, intestines, tonsils and lymph nodes were submitted for bacteriological and mycological analysis. The presence of Clostridium spp., Campylobacter coli and Escherichia coli was detected in gut samples, coli-like bacteria were found in samples of the liver, tonsils and lymph nodes, while Candida sp. was found in the gut and pharynx samples. Toxicological analysis of the samples of blood and gastric content excluded anticoagulant and organophosphorous intoxication as the cause of death. Two years later, paraffin embedded samples of tiger organs were sent to the University of Bern for immunohistochemical analysis (IHC) with positive labelling obtained for the CDV antigen (Plate III, Fig. 2). In brief, the nucleocapsid (N) protein of CDV was detected using a monoclonal antibody D110 diluted 1:2 in TBS. We used goat-anti-mouse antibody diluted 1:40 in TBS as a secondary antibody. Sections were deparaffinized, rehydrated, peroxidase blocked, demasked and incubated with primary and secondary antibodies and visualized with peroxidase antiperoxidase reaction. Due to the similarities in some clinical and pathological findings between infections caused by canine parvovirus and CDV, an IHC staining for parvovirus was performed with negative results. Based on all this, epizootiological, clinical and additional findings, canine distemper was recognized as the cause of the observed condition in the respective animals.DiscussionMajor attention has only been paid to CDV infections in large felids after the epidemics in California (Appel et al. 1994) and Serengeti (Roelke-Parker et al. 1996). However, the disease was probably occurring some time before that, because CD in large felids was for the first time suspected in 1950 when two young lions died with typical neurological signs (Piat 1950). The main clinical symptoms in infected felids include either acute neurologic involvement or progressive intestinal and respiratory signs that, in a case of prolonged course, may lead to neurologic disease. Gross and microscopic lesions in felids infected with CDV are rare when compared to canids (Munson 2001). Gastrointestinal signs in large felids include anorexia and diarrhoea that is sometimes haemorrhagic, as was observed also in our case. Similarly to our findings, intracytoplasmic and intranuclear inclusion bodies can be found in many organs, while generalized depletion of lymphoid organs and associated immunosuppression is a common manifestation of CD (for a review see Beineke et al. 2009). Despite the fact that CDV can cause both intranuclear and intracytoplasmatic inclusion bodies, there is still a possibility that some other viruses participated in their formation. For example, adenoviruses can cause intranuclear inclusion bodies and are occasionally present in the felids (Lakatos et al. 1999). However, based on all other analyses we do not consider adenoviruses as etiological agent of this condition. The main route of virus transmission is aerosol or fomites with the initial infection occurring in the epithelium and lymphoid tissue of the nasopharynx. As several strains of CDV are 4849 known to exist, with different pathogenicity in different species, it is highly possible that certain local strains of the CDV cause disease in large felids and not just one special strain (Barrett 1999). This is evident from the fact that the CDV that caused disease in North American lions is the same as the one isolated from racoons, while the strain isolated from African lions matches the strain isolated from hyenas and domestic dogs. This conclusion, especially based on the observed line of events during the Serengeti outbreak, indicates that a certain adaptation period is required between the virus transmission to another species and the onset of the epidemic form of the disease. In this initial stage, the virus probably requires certain predisposing factors to cause the clinically manifested illness. This, along with the fact that CD is frequently a subclinical infection, could be an answer to the dilemma about why some large felids develop the disease while the rest of the group remain healthy (Myers et al. 1997). In the case of the Zagreb ZOO tigers, the history of neonatal health problems in the cubs in question (low body weight, rachitic animals, etc.) that were overcome by time, represent a potential predisposition to CDV infection (considering that the adult animals and the third cub remained clinically healthy). This is further emphasized by the rapid onset and short duration of the disease, without the involvement of CNS. In most felids, the clinical duration of the disease ranges from 1 day to several weeks and is usually fatal. Regarding the possible source of virus, one of the explanations are zoo-keepers that own domestic dogs and could carry the virus on their clothes (virus is relatively unstable in the environment requiring closer contact); another is the abundant free-living marten population as it is known that martens are highly susceptible to CDV (Deem et al. 2000; Frölich et al. 2000). The third possibility are subclinically infected adult tigers and lions (kept in an adjacent cage) that could spread viruses to their environment. In one example, Ramanathan et al. (2007) analysed blood samples from 56 apparently healthy captive Asiatic lions (Panthera leo persica) for the presence of antibodies against CDV, feline parvovirus (FPV), feline immunodeficiency virus (FIV) and feline leukemia virus (FeLV). Among them, 49 were positive for CDV and all 56 for FPV. Such a high prevalence of subclinically infected captive lions gives rise to the possibility of transmission of the virus to cubs, especially if it is known that CDV is relatively unstable in the environment, requiring close contact between infected and non-infected animals.AcknowledgmentThe study was supported by grants Nos. 053-0532264-2260 and 053-0532400-2399, of the Ministry of Science, Education and Sport of the Republic of Croatia.ReferencesAppel MJG, Yates RA, Foley GL, Bernstein JJ, Santinelli S, Spelman LH, Miller LD, Arp LH, Anderson M, Barr M 1994: Canine distemper epizootic in lions, tigers, and leopards in North America. J Vet Diagn Invest 6: 277-288Barrett T 1999: Morbillivirus infections, with special emphasis on morbiliviruses of carnivores. Vet Microbiol 69: 3-13Beineke A, Puff C, Seehusen F, Baumgärtner W 2009: Pathogenesis and immunopathology of systemic and nervous canine distemper. Vet Immunol Immunopathol 127: 1-18Deem SL, Spelman LH, Yates RA, Montali RJ 2000: Canine distemper in terrestrial carnivore: a review. J Zoo Wildl Med 31: 441-451Frölich K, Czupalla O, Haas L, Hentschke J, Dedek J, Fickel J 2000: Epizootiological investigations of canine distemper virus in free-ranging carnivores from Germany. Vet Microbiol 74: 283-292Kennedy S, Kuiken T, Jepson PD, Deaville R, Forsyth M, Barrett T, van de Bildt MWG, Osterhaus ADME, Eybatov T, Duck C, Kydyrmanov A, Mitrofanov I, Wilson S 2000: Mass die-off of Caspian seals caused by canine distemper virus. Emerg Infect Dis 6: 637-639Lakatos B, Knotek Z, Farkas J, Ádám É, Dobay O, Nász I 1999: Adenovirus infection in cats. An epidemiological survey in the Czech Republic. Acta Vet Brno 68: 275-280Munson L 2001: Feline morbilivirus infection. In: Williams ES, Barker IK (eds) Infectious diseases of Wild Mammals 3rd edition. Blackwell Publishing, London, pp. 59-6250Myers DL, Zurbriggen A, Lutz H, Pospischil A 1997: Distemper: Not a New Disease in Lions and Tigers. Clin Diagn Lab Immunol 4: 180-184Piat BL 1950: Susceptibility of young lions to dog distemper. Bulletin Service d’Elevage Industrial Animales Afrique Occidental Francais 3: 39-40Ramanathan A, Malik PK, Prasad G 2007: Seroepizootiological survey for selected viral infections in captive Asiatic lions (Panthera leo persica) from Western India. J Zoo Wildl Med 38: 400-408Roelke-Parker ME, Munson L, Packer C, Kock R, Cleaveland S, Carpenter M, O’Brien SJ, Pospischil A, Hofmann-Lehmann R, Lutz H, Mwamengele GLM, Mgasam N, Machange GA, Summers BA, Appel MJG 1996: A canine distemper virus epidemic in Serengeti lions (Panthera leo). Nature 379: 441-445.van de Bildt MWG, Kuiken T, Visee AM, Lema S, Fitzjohn TR, Osterhaus ADME 2002: Distemper outbreak and its effect on african wild dog conservation. Emerg Infect Dis 8: 211-213Williams ES, Thorne ET, Appel MJG, Belitsky DW 1988: Canine distemper in black-footed ferrets (Mustela nigripes) from Wyoming. J Wildl Dis 24: 385-398Plate IIIKonjević D. et al.: Canine distemper ... pp. 47-50Fig. 1. Intestine. Inclusion bodies (arrow). HE × 100.Fig. 2. Immunohistochemistry. Positive staining for canine distemper virus (arrows).。
头孢他啶英文说明书
1PRODUCT INFORMATIONCEPTAZ®2(ceftazidime for injection)3L-arginine formulation45For Intravenous or Intramuscular Use678DESCRIPTION: Ceftazidime is a semisynthetic, broad-spectrum, beta-lactam antibiotic forparenteral administration. It is the pentahydrate of pyridinium, 1-[[7-[[(2-amino-4-thiazolyl)[(1-910carboxy-1-methylethoxy)imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-11en-3-yl]methyl]-, hydroxide, inner salt, [6R-[6α,7β(Z)]]. It has the following structure:12131415The empirical formula is C22H32N6O12S2, representing a molecular weight of 636.6.CEPTAZ is a sterile, dry mixture of ceftazidime pentahydrate and L-arginine. The L-arginine1617is at a concentration of 349 mg/g of ceftazidime activity. CEPTAZ dissolves without the18evolution of gas. The product contains no sodium ion. Solutions of CEPTAZ range in color from 19light yellow to amber, depending on the diluent and volume used. The pH of freshly constituted 20solutions usually ranges from 5 to 7.5.2122CLINICAL PHARMACOLOGY: After intravenous (IV) administration of 500-mg and 1-g doses of ceftazidime over 5 minutes to normal adult male volunteers, mean peak serum2324concentrations of 45 and 90 mcg/mL, respectively, were achieved. After IV infusion of 500-mg, 251-g, and 2-g doses of ceftazidime over 20 to 30 minutes to normal adult male volunteers, mean peak serum concentrations of 42, 69, and 170 mcg/mL, respectively, were achieved. The average2627serum concentrations following IV infusion of 500-mg, 1-g, and 2-g doses to these volunteers28over an 8-hour interval are given in Table 1.2930Table 1Ceftazidime Serum Concentrations (mcg/mL)IV Dose 0.5 h 1 h 2 h 4 h 8 hmg 42 25 12 6 2 500g 60 39 23 11 31g 129 75 42 13 523132The absorption and elimination of ceftazidime were directly proportional to the size of the33dose. The half-life following IV administration was approximately 1.9 hours. Less than 10% of 34ceftazidime was protein bound. The degree of protein binding was independent of concentration.There was no evidence of accumulation of ceftazidime in the serum in individuals with normal3536renal function following multiple IV doses of 1 and 2 g every 8 hours for 10 days.37Following intramuscular (IM) administration of 500-mg and 1-g doses of ceftazidime to38normal adult volunteers, the mean peak serum concentrations were 17 and 39 mcg/mL,39respectively, at approximately 1 hour. Serum concentrations remained above 4 mcg/mL for 6 and 408 hours after the IM administration of 500-mg and 1-g doses, respectively. The half-life of41ceftazidime in these volunteers was approximately 2 hours.42The presence of hepatic dysfunction had no effect on the pharmacokinetics of ceftazidime in 43individuals administered 2 g intravenously every 8 hours for 5 days. Therefore, a dosage44adjustment from the normal recommended dosage is not required for patients with hepatic45dysfunction, provided renal function is not impaired.46Approximately 80% to 90% of an IM or IV dose of ceftazidime is excreted unchanged by the 47kidneys over a 24-hour period. After the IV administration of single 500-mg or 1-g doses,approximately 50% of the dose appeared in the urine in the first 2 hours. An additional 20% was4849excreted between 2 and 4 hours after dosing, and approximately another 12% of the doseappeared in the urine between 4 and 8 hours later. The elimination of ceftazidime by the kidneys5051resulted in high therapeutic concentrations in the urine.52The mean renal clearance of ceftazidime was approximately 100 mL/min. The calculated53plasma clearance of approximately 115 mL/min indicated nearly complete elimination of54ceftazidime by the renal route. Administration of probenecid before dosing had no effect on the 55elimination kinetics of ceftazidime. This suggested that ceftazidime is eliminated by glomerular 56filtration and is not actively secreted by renal tubular mechanisms.57Since ceftazidime is eliminated almost solely by the kidneys, its serum half-life is significantly 58prolonged in patients with impaired renal function. Consequently, dosage adjustments in such59patients as described in the DOSAGE AND ADMINISTRATION section are suggested.60Ceftazidime concentrations achieved in specific body tissues and fluids are depicted in61Table 2.62Table 2: Ceftazidime Concentrations in Body Tissues and Fluids 63Tissue or Fluid Dose/ RouteNo. ofPatientsTime ofSamplePostdoseAverage Tissueor Fluid Level(mcg/mL ormcg/g)Urine 500 mg IM 6 0-2 h 2,100.02 g IV 6 0-2 h 12,000.0Bile 2 g IV 3 90 min 36.4Synovial fluid 2 g IV 13 2 h 25.6Peritoneal fluid 2 g IV 8 2 h 48.6Sputum 1 g IV 8 1 h 9.0Cerebrospinal fluid 2 g q8h IV 5 120 min 9.8(inflamed meninges) 2 g q8h IV 6 180 min 9.4Aqueous humor 2 g IV 13 1-3 h 11.0Blister fluid 1 g IV 7 2-3 h 19.7Lymphatic fluid 1 g IV 7 2-3 h 23.4Bone 2 g IV 8 0.67 h 31.1Heart muscle 2 g IV 35 30-280 min 12.7Skin 2 g IV 22 30-180 min 6.6Skeletal muscle 2 g IV 35 30-280 min 9.4Myometrium 2 g IV 31 1-2 h 18.764Microbiology: Ceftazidime is bactericidal in action, exerting its effect by inhibition of enzymes 65responsible for cell-wall synthesis. A wide range of gram-negative organisms is susceptible to66ceftazidime in vitro, including strains resistant to gentamicin and other aminoglycosides. In67addition, ceftazidime has been shown to be active against gram-positive organisms. It is highly 68stable to most clinically important beta-lactamases, plasmid or chromosomal, which are produced 69by both gram-negative and gram-positive organisms and, consequently, is active against many 70strains resistant to ampicillin and other cephalosporins.71Ceftazidime has been shown to be active against the following organisms both in vitro and in 72clinical infections (see INDICATIONS AND USAGE).7374Aerobes,Gram-negative:Citrobacter spp., including Citrobacter freundii and Citrobacter75diversus; Enterobacter spp., including Enterobacter cloacae and Enterobacter aerogenes;76Escherichia coli; Haemophilus influenzae, including ampicillin-resistant strains; Klebsiella spp.77(including Klebsiella pneumoniae); Neisseria meningitidis; Proteus mirabilis; Proteus vulgaris;78Pseudomonas spp. (including Pseudomonas aeruginosa); and Serratia spp.79Aerobes, Gram-positive:Staphylococcus aureus, including penicillinase- and non–80penicillinase-producing strains; Streptococcus agalactiae (group B streptococci); Streptococcus 81pneumoniae; and Streptococcus pyogenes (group A beta-hemolytic streptococci).Anaerobes:Bacteroides spp. (NOTE: many strains of Bacteroides fragilis are resistant).8283Ceftazidime has been shown to be active in vitro against most strains of the following organisms; however, the clinical significance of this activity is unknown: Acinetobacter spp.,8485Clostridium spp. (not including Clostridium difficile), Haemophilus parainfluenzae, Morganella 86morganii (formerly Proteus morganii), Neisseria gonorrhoeae, Peptococcus spp.,87Peptostreptococcus spp., Providencia spp. (including Providencia rettgeri, formerly Proteus88rettgeri), Salmonella spp., Shigella spp., Staphylococcus epidermidis, and Yersinia89enterocolitica.Ceftazidime and the aminoglycosides have been shown to be synergistic in vitro against9091Pseudomonas aeruginosa and the enterobacteriaceae. Ceftazidime and carbenicillin have also 92been shown to be synergistic in vitro against Pseudomonas aeruginosa.93Ceftazidime is not active in vitro against methicillin-resistant staphylococci, Streptococcus94faecalis and many other enterococci, Listeria monocytogenes, Campylobacter spp., or95Clostridium difficile.96Susceptibility Tests:Diffusion Techniques:Quantitative methods that require measurement of 97zone diameters give an estimate of antibiotic susceptibility. One such procedure1-3 has been98recommended for use with disks to test susceptibility to ceftazidime.99Reports from the laboratory giving results of the standard single-disk susceptibility test with a 30-mcg ceftazidime disk should be interpreted according to the following criteria:100101Susceptible organisms produce zones of 18 mm or greater, indicating that the test organism 102is likely to respond to therapy.Organisms that produce zones of 15 to 17 mm are expected to be susceptible if high dosage 103104is used or if the infection is confined to tissues and fluids (e.g., urine) in which high antibiotic 105levels are attained.106Resistant organisms produce zones of 14 mm or less, indicating that other therapy should be 107selected.108Organisms should be tested with the ceftazidime disk since ceftazidime has been shown by in 109vitro tests to be active against certain strains found resistant when other beta-lactam disks are 110used.111Standardized procedures require the use of laboratory control organisms. The 30-mcg ceftazidime disk should give zone diameters between 25 and 32 mm for Escherichia coli112113ATCC 25922. For Pseudomonas aeruginosa ATCC 27853, the zone diameters should bebetween 22 and 29 mm. For Staphylococcus aureus ATCC 25923, the zone diameters should be 114115between 16 and 20 mm.116Dilution Techniques:In other susceptibility testing procedures, e.g., ICS agar dilution or the 117equivalent, a bacterial isolate may be considered susceptible if the minimum inhibitory118concentration (MIC) value for ceftazidime is not more than 16 mcg/mL. Organisms are119considered resistant to ceftazidime if the MIC is ≥64 mcg/mL. Organisms having an MIC value 120of <64 mcg/mL but >16 mcg/mL are expected to be susceptible if high dosage is used or if the 121infection is confined to tissues and fluids (e.g., urine) in which high antibiotic levels are attained. 122As with standard diffusion methods, dilution procedures require the use of laboratory control 123organisms. Standard ceftazidime powder should give MIC values in the range of 4 to 16 mcg/mL 124for Staphylococcus aureus ATCC 25923. For Escherichia coli ATCC 25922, the MIC range125should be between 0.125 and 0.5 mcg/mL. For Pseudomonas aeruginosa ATCC 27853, the MIC 126range should be between 0.5 and 2 mcg/mL.127128INDICATIONS AND USAGE: CEPTAZ is indicated for the treatment of patients with129infections caused by susceptible strains of the designated organisms in the following diseases: 1301.Lower Respiratory Tract Infections, including pneumonia, caused by Pseudomonas131aeruginosa and other Pseudomonas spp.; Haemophilus influenzae, including132ampicillin-resistant strains; Klebsiella spp.; Enterobacter spp.; Proteus mirabilis; Escherichiacoli; Serratia spp.; Citrobacter spp.; Streptococcus pneumoniae; and Staphylococcus aureus 133134(methicillin-susceptible strains).1352.Skin and Skin-Structure Infections caused by Pseudomonas aeruginosa; Klebsiella spp.; 136Escherichia coli; Proteus spp., including Proteus mirabilis and indole-positive Proteus;137Enterobacter spp.; Serratia spp.; Staphylococcus aureus (methicillin-susceptible strains); and 138Streptococcus pyogenes (group A beta-hemolytic streptococci).1393. Urinary Tract Infections, both complicated and uncomplicated, caused by Pseudomonas140aeruginosa; Enterobacter spp.; Proteus spp., including Proteus mirabilis and indole-positive 141Proteus; Klebsiella spp.; and Escherichia coli.4.Bacterial Septicemia caused by Pseudomonas aeruginosa, Klebsiella spp., Haemophilus142143influenzae, Escherichia coli, Serratia spp., Streptococcus pneumoniae, and Staphylococcusaureus (methicillin-susceptible strains).1441455. Bone and Joint Infections caused by Pseudomonas aeruginosa,Klebsiella spp., Enterobacter 146spp., and Staphylococcus aureus (methicillin-susceptible strains).1476.Gynecologic Infections, including endometritis, pelvic cellulitis, and other infections of the 148female genital tract caused by Escherichia coli.1497.Intra-abdominal Infections, including peritonitis caused by Escherichia coli, Klebsiella spp.,and Staphylococcus aureus (methicillin-susceptible strains) and polymicrobial infections150151caused by aerobic and anaerobic organisms and Bacteroides spp. (many strains of Bacteroides 152fragilis are resistant).1538.Central Nervous System Infections, including meningitis, caused by Haemophilus influenzae 154and Neisseria meningitidis. Ceftazidime has also been used successfully in a limited number of 155cases of meningitis due to Pseudomonas aeruginosa and Streptococcus pneumoniae.156Specimens for bacterial cultures should be obtained before therapy in order to isolate and157identify causative organisms and to determine their susceptibility to ceftazidime. Therapy may be 158instituted before results of susceptibility studies are known; however, once these results become 159available, the antibiotic treatment should be adjusted accordingly.CEPTAZ may be used alone in cases of confirmed or suspected sepsis. Ceftazidime has been 160161used successfully in clinical trials as empiric therapy in cases where various concomitant162therapies with other antibiotics have been used.163CEPTAZ may also be used concomitantly with other antibiotics, such as aminoglycosides, 164vancomycin, and clindamycin; in severe and life-threatening infections; and in the165immunocompromised patient (see COMPATIBILITY AND STABILITY). When such166concomitant treatment is appropriate, prescribing information in the labeling for the otherantibiotics should be followed. The dosage depends on the severity of the infection and the167168patient's condition.169170CONTRAINDICATIONS: CEPTAZ is contraindicated in patients who have shown171hypersensitivity to ceftazidime or the cephalosporin group of antibiotics.172173WARNINGS: BEFORE THERAPY WITH CEPTAZ IS INSTITUTED, CAREFUL INQUIRY 174SHOULD BE MADE TO DETERMINE WHETHER THE PATIENT HAS HAD PREVIOUS 175HYPERSENSITIVITY REACTIONS TO CEFTAZIDIME, CEPHALOSPORINS,176PENICILLINS, OR OTHER DRUGS. IF THIS PRODUCT IS TO BE GIVEN TOPENICILLIN-SENSITIVE PATIENTS, CAUTION SHOULD BE EXERCISED BECAUSE 177178CROSS-HYPERSENSITIVITY AMONG BETA-LACTAM ANTIBIOTICS HAS BEENCLEARLY DOCUMENTED AND MAY OCCUR IN UP TO 10% OF PATIENTS WITH A 179180HISTORY OF PENICILLIN ALLERGY. IF AN ALLERGIC REACTION TO CEPTAZ181OCCURS, DISCONTINUE THE DRUG. SERIOUS ACUTE HYPERSENSITIVITY182REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER183EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, 184CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS185CLINICALLY INDICATED.186Pseudomembranous colitis has been reported with nearly all antibacterial agents,187including ceftazidime, and may range in severity from mild to life threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhea subsequent to 188189the administration of antibacterial agents.Treatment with antibacterial agents alters the normal flora of the colon and may permit190191overgrowth of clostridia. Studies indicate that a toxin produced by Clostridium difficile is one 192primary cause of "antibiotic-associated colitis."After the diagnosis of pseudomembranous colitis has been established, appropriate therapeutic 193194measures should be initiated. Mild cases of pseudomembranous colitis usually respond to drug195discontinuation alone. In moderate to severe cases, consideration should be given to management196with fluids and electrolytes, protein supplementation, and treatment with an antibacterial drug197clinically effective against Clostridium difficile colitis.198Elevated levels of ceftazidime in patients with renal insufficiency can lead to seizures,encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia (see199200PRECAUTIONS).201202PRECAUTIONS:203General: High and prolonged serum ceftazidime concentrations can occur from usual dosages in204patients with transient or persistent reduction of urinary output because of renal insufficiency.205The total daily dosage should be reduced when ceftazidime is administered to patients with renal206insufficiency (see DOSAGE AND ADMINISTRATION). Elevated levels of ceftazidime in thesepatients can lead to seizures, encephalopathy, coma, asterixis, neuromuscular excitability, and 207208myoclonia. Continued dosage should be determined by degree of renal impairment, severity ofinfection, and susceptibility of the causative organisms.209210As with other antibiotics, prolonged use of CEPTAZ may result in overgrowth of211nonsusceptible organisms. Repeated evaluation of the patient's condition is essential. If212superinfection occurs during therapy, appropriate measures should be taken.213Inducible type I beta-lactamase resistance has been noted with some organisms (e.g.,214Enterobacter spp.,Pseudomonas spp., and Serratia spp.). As with other extended-spectrum215beta-lactam antibiotics, resistance can develop during therapy, leading to clinical failure in some216cases. When treating infections caused by these organisms, periodic susceptibility testing should217be performed when clinically appropriate. If patients fail to respond to monotherapy, anaminoglycoside or similar agent should be considered.218219Cephalosporins may be associated with a fall in prothrombin activity. Those at risk includepatients with renal or hepatic impairment, or poor nutritional state, as well as patients receiving a 220221protracted course of antimicrobial therapy. Prothrombin time should be monitored in patients at222risk and exogenous vitamin K administered as indicated.CEPTAZ should be prescribed with caution in individuals with a history of gastrointestinal 223224disease, particularly colitis.225Arginine has been shown to alter glucose metabolism and elevate serum potassium transiently 226when administered at 50 times the recommended dose. The effect of lower dosing is not known. 227Distal necrosis can occur after inadvertent intra-arterial administration of ceftazidime.228Drug Interactions: Nephrotoxicity has been reported following concomitant administration of 229cephalosporins with aminoglycoside antibiotics or potent diuretics such as furosemide. Renal 230function should be carefully monitored, especially if higher dosages of the aminoglycosides are to 231be administered or if therapy is prolonged, because of the potential nephrotoxicity and ototoxicity of aminoglycosidic antibiotics. Nephrotoxicity and ototoxicity were not noted when ceftazidime 232233was given alone in clinical trials.Chloramphenicol has been shown to be antagonistic to beta-lactam antibiotics, including234235ceftazidime, based on in vitro studies and time kill curves with enteric gram-negative bacilli. Due 236to the possibility of antagonism in vivo, particularly when bactericidal activity is desired, this 237drug combination should be avoided.238Drug/Laboratory Test Interactions: The administration of ceftazidime may result in a239false-positive reaction for glucose in the urine when using CLINITEST® tablets, Benedict'ssolution, or Fehling's solution. It is recommended that glucose tests based on enzymatic glucose 240241oxidase reactions (such as CLINISTIX®) be used.242Carcinogenesis, Mutagenesis, Impairment of Fertility: Long-term studies in animals have not 243been performed to evaluate carcinogenic potential. However, a mouse Micronucleus test and an 244Ames test were both negative for mutagenic effects.245Pregnancy:Teratogenic Effects: Pregnancy Category B. Reproduction studies have been246performed in mice and rats at doses up to 40 times the human dose and have revealed no evidence 247of impaired fertility or harm to the fetus due to ceftazidime. CEPTAZ at 23 times the human dose 248was not teratogenic or embryotoxic in a rat reproduction study. There are, however, no adequate 249and well-controlled studies in pregnant women. Because animal reproduction studies are notalways predictive of human response, this drug should be used during pregnancy only if clearly 250251needed.252Nursing Mothers: Ceftazidime is excreted in human milk in low concentrations. It is not knownwhether the arginine component of this product is excreted in human milk. Because many drugs 253254are excreted in human milk and because safety of the arginine component of CEPTAZ in nursing 255infants has not been established, a decision should be made whether to discontinue nursing or to 256discontinue the drug, taking into account the importance of the drug to the mother.257Pediatric Use: Safety of the arginine component of CEPTAZ in neonates, infants, and children 258has not been established. This product is for use in patients 12 years and older. If treatment with ceftazidime is indicated for neonates, infants, or children, a sodium carbonate formulation should 259260be used.261262ADVERSE REACTIONS: The following adverse effects from clinical trials were considered to 263be either related to ceftazidime therapy or were of uncertain etiology. The most common were 264local reactions following IV injection and allergic and gastrointestinal reactions. No265disulfiramlike reactions were reported.266Local Effects, reported in fewer than 2% of patients, were phlebitis and inflammation at the site of injection (1 in 69 patients).267268Hypersensitivity Reactions, reported in 2% of patients, were pruritus, rash, and fever.Immediate reactions, generally manifested by rash and/or pruritus, occurred in 1 in 285 patients. 269270Toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme have also been 271reported with cephalosporin antibiotics, including ceftazidime. Angioedema and anaphylaxis 272(bronchospasm and/or hypotension) have been reported very rarely.273Gastrointestinal Symptoms, reported in fewer than 2% of patients, were diarrhea (1 in 78),274nausea (1 in 156), vomiting (1 in 500), and abdominal pain (1 in 416). The onset of275pseudomembranous colitis symptoms may occur during or after treatment (see WARNINGS). 276Central Nervous System Reactions (fewer than 1%) included headache, dizziness, and277paresthesia. Seizures have been reported with several cephalosporins, including ceftazidime. In addition, encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been 278279reported in renally impaired patients treated with unadjusted dosage regimens of ceftazidime (see PRECAUTIONS: General).280281Less Frequent Adverse Events (fewer than 1%) were candidiasis (including oral thrush) and 282vaginitis.Hematologic: Rare cases of hemolytic anemia have been reported.283284Laboratory Test Changes noted during ceftazidime clinical trials were transient and included: 285eosinophilia (1 in 13), positive Coombs' test without hemolysis (1 in 23), thrombocytosis (1 in 28645), and slight elevations in one or more of the hepatic enzymes, aspartate aminotransferase287(AST, SGOT) (1 in 16), alanine aminotransferase (ALT, SGPT) (1 in 15), LDH (1 in 18), GGT (1 288in 19), and alkaline phosphatase (1 in 23). As with some other cephalosporins, transient289elevations of blood urea, blood urea nitrogen, and/or serum creatinine were observed290occasionally. Transient leukopenia, neutropenia, agranulocytosis, thrombocytopenia, and291lymphocytosis were seen very rarely.292293POSTMARKETING EXPERIENCE WITH CEPTAZ PRODUCTS: In addition to theadverse events reported during clinical trials, the following events have been observed during 294295clinical practice in patients treated with CEPTAZ and were reported spontaneously. For some of 296these events, data are insufficient to allow an estimate of incidence or to establish causation.297General: Anaphylaxis; allergic reactions, which, in rare instances, were severe (e.g.,298cardiopulmonary arrest); urticaria; pain at injection site.299Hepatobiliary Tract: Hyperbilirubinemia, jaundice.300Renal and Genitourinary: Renal impairment.301Cephalosporin-Class Adverse Reactions: In addition to the adverse reactions listed above that 302have been observed in patients treated with ceftazidime, the following adverse reactions and303altered laboratory tests have been reported for cephalosporin-class antibiotics:304Adverse Reactions:Colitis, toxic nephropathy, hepatic dysfunction including cholestasis, 305aplastic anemia, hemorrhage.306Altered Laboratory Tests:Prolonged prothrombin time, false-positive test for urinary307glucose, pancytopenia.308309OVERDOSAGE: Ceftazidime overdosage has occurred in patients with renal failure. Reactions 310have included seizure activity, encephalopathy, asterixis, neuromuscular excitability, and coma. 311Patients who receive an acute overdosage should be carefully observed and given supportive312treatment. In the presence of renal insufficiency, hemodialysis or peritoneal dialysis may aid inthe removal of ceftazidime from the body.313314315DOSAGE AND ADMINISTRATION:Dosage: The usual adult dosage is 1 gram administered intravenously or intramuscularly every 8 316317to 12 hours. The dosage and route should be determined by the susceptibility of the causative 318organisms, the severity of infection, and the condition and renal function of the patient.319The guidelines for dosage of CEPTAZ are listed in Table 3. The following dosage schedule is 320recommended.321Table 3: Recommended Dosage Schedule322DoseFrequency Patients 12 years and older*Usual recommended dosage 1 gram IV or IM q8-12hUncomplicated urinary tract infections 250 mg IV or IM q12hBone and joint infections 2 grams IV q12hComplicated urinary tract infections 500 mg IV or IM q8-12hUncomplicated pneumonia; mild skin and skin- structure infections 500 mg-1 gramIV or IM q8hSerious gynecologic and intra-abdominal infections 2 grams IV q8h Meningitis 2 grams IV q8h Very severe life-threatening infections, especiallyin immunocompromised patients 2 grams IV q8hLung infections caused by Pseudomonas spp. in patients with cystic fibrosis with normal renal function†30-50 mg/kg IVto a maximumof 6 grams per day q8h* This product is for use in patients 12 years and older. If treatment with ceftazidime is323indicated for patients less than 12 years old, a sodium carbonate formulation should324be used.325†Although clinical improvement has been shown, bacteriologic cures cannot be326expected in patients with chronic respiratory disease and cystic fibrosis.327328Impaired Hepatic Function: No adjustment in dosage is required for patients with hepatic 329dysfunction.330Impaired Renal Function: Ceftazidime is excreted by the kidneys, almost exclusively by 331glomerular filtration. Therefore, in patients with impaired renal function (glomerular filtration 332rate [GFR]<50 mL/min), it is recommended that the dosage of ceftazidime be reduced to333compensate for its slower excretion. In patients with suspected renal insufficiency, an initial334loading dose of 1 gram of CEPTAZ may be given. An estimate of GFR should be made to335determine the appropriate maintenance dosage. The recommended dosage is presented in Table 4. 336。
血培养胎儿弯曲菌引起的思考
血培养胎儿弯曲菌引起的思考发布时间:2023-01-04T03:51:47.358Z 来源:《医师在线》2022年28期作者:王秀菊刘倩倩单星星通讯作者[导读] 目的:通过对一例送检三瓶血培养,在120h内仅有一瓶仪器报阳并鉴定出胎儿弯曲菌、另外两瓶“阴性瓶”经转种后均有胎儿弯曲菌胎儿亚种生长的案例进行分析王秀菊刘倩倩单星星通讯作者南京金域医学检验所有限公司江苏南京 210042摘要目的:通过对一例送检三瓶血培养,在120h内仅有一瓶仪器报阳并鉴定出胎儿弯曲菌、另外两瓶“阴性瓶”经转种后均有胎儿弯曲菌胎儿亚种生长的案例进行分析,思考怎样提高实验室关于血培养检出少见菌及疑难菌的能力。
方法:通过革兰染色涂片镜检及郑州安图质谱鉴定仪和法国梅里埃质谱鉴定仪认识胎儿弯曲菌,了解其生长特性,同时关注血培养仪检测原理及细菌生长曲线,对疑似“阴性瓶”进行验证。
结果:检出的细菌经过染色及质谱鉴定确认为胎儿弯曲菌,“阴性瓶”中生长的细菌经过确认与报阳瓶中结果一致,这是一例由胎儿弯曲菌感染所引起的菌血症。
结论:少见菌引起的血流感染常常由于细菌生长缓慢导致结果“假阴性”,实验室应当认真慎重对待每一个报阳血瓶及生长曲线,并关注感染病原体,发放出最值得有参考意义的检测报告单。
关键词:胎儿弯曲菌假阴性菌血症Abstract Objective:To analyze a case in which three blood culture vials were sent, only one vial was positive and identified Campylobacter fetus within 120h, and the other two "negative vials" had the growth of Campylobacter fetus after the transfer, and to consider how to improve the laboratory's ability to detect rare and difficult bacteria in blood culture. Methods: To recognize the growth characteristics of Campylobacter fetus by microscopic examination of Gram stained smear and mass spectrometer of Zhengzhou Antoine and French Mérieux, and to verify the suspected "negative vials" by paying attention to the detection principle of blood culture and bacterial growth curve. Results: The bacteria detected were confirmed to be Campylobacter fetus after staining and mass spectrometry, and the bacteria grown in the "negative bottle" were confirmed to be the same as those in the positive bottle, which was a case of bacteremia caused by Campylobacter fetus infection. Conclusion: Bloodstream infections caused by rare bacteria often result in "false negative" results due to slow bacterial growth, and laboratories should treat each positive vial and growth curve carefully and pay attention to the infecting pathogen to issue the most informative test report.Keywords: Campylobacter fetus, pseudonegative, bacteremia基本信息:1.某一因原因不明持续性低烧入院的患者,送检血培养+药敏项目,实验室采用郑州安图生物有限公司生产的血瓶,包括两瓶需氧血培养和一瓶厌氧血培养。
三种酸化剂最小杀菌浓度(MBC)的测定
三种酸化剂最小杀菌浓度(MBC)的测定关飞;尤永君;安俊峰【摘要】酸化剂具有调节动物肠道的pH值,激活消化酶,改善营养物质的消化和吸收,以及增强机体免疫力等作用.本文就三种酸化剂产品对大肠杆菌、金黄色葡萄球菌和黄曲霉菌的最小杀菌浓度进行了试验观察,试验结果表明:三种酸化剂产品在一定浓度内对三种病原微生物都具有杀灭作用,具有替代某些抗生素的潜能.【期刊名称】《中国动物保健》【年(卷),期】2015(017)004【总页数】3页(P71-73)【关键词】酸化剂;细菌;霉菌;最小杀菌浓度【作者】关飞;尤永君;安俊峰【作者单位】天津瑞普生物技术股份有限公司天津市 300308;天津瑞普生物技术股份有限公司天津市 300308;天津瑞普生物技术股份有限公司天津市 300308【正文语种】中文随着人们对食品安全日益重视,动物性食品的抗生素药物残留问题亟待解决,国内外正寻求能够替代抗生素的饲料添加剂。
目前,在畜牧生产中应用酸化剂已得到了迅速的发展,经研究报道平[1-6]酸化剂对调节动物肠道pH值,提高动物机体内消化酶的活性,提高饲料利用率,改善肠道正常菌群,杀灭或抑制有害菌的生长繁殖,促进动物生长等方面有重要作用。
本文就酸化剂的杀菌、抑菌作用做了相关实验,旨在说明酸化剂对某些有害菌具有杀灭和抑制作用,为酸化剂在生产实际的应用提供一定理论依据。
A酸化剂:维乐欣(主要成分:乙酸、甲酸、丙酸、丁酸、柠檬酸、苹果酸、乳酸及其盐,批号:津饲预字[2010]009924号);B酸化剂(主要成分:甲酸、乙酸、甲酸胺)、C酸化剂(主要成分:丙酸、苹果酸、甲酸、富马酸)为普通酸化剂,无批号;pH测定仪(TP210精密便携式pH计,购自北京时代新维测控设备有限公司),大肠杆菌标准株、金黄色葡萄球菌标准(购自广东环凯微生物科技有限公司)、黄曲霉菌分离株;灭菌琼脂培养基、普通自来水、灭菌蒸馏水、灭菌肉体培养基、灭菌孟加拉红培养基。
由于在临床养殖过程中A酸化剂维乐欣建议使用浓度有0.05%、0.1%、0.2%三种,所以在做抑菌试验的时候将三种酸化剂分别稀释成0.05%、0.1%、0.2%三个浓度梯度,以便观察其抑菌效果。
- 1、下载文档前请自行甄别文档内容的完整性,平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益,请联系客服反馈,我们会尽快为您处理(人工客服工作时间:9:00-18:30)。
Campylobacter Infection as a Trigger for Guillain-Barre´Syndrome in EgyptThomas F.Wierzba1¤a*,Ibrahim Adib Abdel-Messih1,Bayoumi Gharib2,Shahida Baqar3,Amina Hendaui4,Ibrahim Khalil2,Tarek A.Omar3,Hamed E.Khayat5,Shannon D.Putnam1,John W.Sanders6¤b, Lai-King Ng7,Lawrence J.Price7,Daniel A.Scott8¤c,Robert R.Frenck1¤d1US Naval Medical Research Unit No.3,Cairo,Egypt,2Neurology Department,Alexandria University Hospitals,Alexandria,Egypt,3Naval Medical Research Center,Silver Spring,Maryland,United States of America,4Neurology Department,Cairo University Hospitals,Cairo,Egypt,5Neurology Department,Ain Shams University Children’s Hospital,Ain Shams,Egypt,6US Naval Medical Research Unit No.3,Cairo,Egypt,7Bacteriology and Enteric Diseases Program,National Microbiology Laboratory, Winnipeg,Manitoba,Canada,8Naval Medical Research Center,Bethesda,Maryland,United States of AmericaAbstractBackground:Most studies of Campylobacter infection triggering Guillain-Barre´Syndrome(GBS)are conducted in western nations were Campylobacter infection and immunity is relatively rare.In this study,we explored Campylobacter infections, Campylobacter serotypes,autoantibodies to gangliosides,and GBS in Egypt,a country where Campylobacter exposure is common.Methods:GBS cases(n=133)were compared to age-and hospital-matched patient controls(n=374).A nerve conduction study was performed on cases and a clinical history,serum sample,and stool specimen obtained for all subjects.Results:Most(63.3%)cases were demyelinating type;median age four years.Cases were more likely than controls to have diarrhea(29.5%vs.22.5%,Adjusted Odds Ratio(ORa)=1.69,P=0.03),to have higher geometric mean IgM anti-Campylobacter antibody titers(8.18vs.7.25P,0.001),and to produce antiganglioside antibodies(e.g.,anti-Gd1a,35.3vs.11.5,ORa=4.39,P,0.0001).Of26Penner:Lior Campylobacter serotypes isolated,only one(41:27,C.jejuni,P=0.02)wasassociated with GBS.Conclusions:Unlike results from western nations,data suggested that GBS cases were primarily in the young and cases and many controls had a history of infection to a variety of Campylobacter serotypes.Still,the higher rates of diarrhea and greater antibody production against Campylobacter and gangliosides in GBS patients were consistent with findings from western countries.Citation:Wierzba TF,Abdel-Messih IA,Gharib B,Baqar S,Hendaui A,et al.(2008)Campylobacter Infection as a Trigger for Guillain-Barre´Syndrome in Egypt.PLoS ONE3(11):e3674.doi:10.1371/journal.pone.0003674Editor:Jacques Zimmer,Centre de Recherche Public-Sante´,LuxembourgReceived September23,2008;Accepted October9,2008;Published November12,2008This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration which stipulates that,once placed in the public domain,this work may be freely reproduced,distributed,transmitted,modified,built upon,or otherwise used by anyone for any lawful purpose.Funding:Funding was provided by the Military Infectious Diseases Research Program of the United States Department of Defense(Work Unit:6000.RAD1.DA3.A0308).The funders had no role in study design,data collection and analysis,decision to publish,or preparation of the manuscript.Competing Interests:The authors have declared that no competing interests exist.*E-mail:Director@.kh¤a Current address:US Naval Medical Research Unit No.2,Jakarta,Indonesia¤b Current address:US Naval Medical Research Center,Lima,Peru¤c Current address:Wyeth Research,Pearl River,New York,United States of America¤d Current address:Cincinnati Children’s Hospital Medical Center,Cincinnati,Ohio,United States of AmericaIntroductionCampylobacter–associated diarrhea is common in developing countries and residents experience repeated attacks[1].In Egypt, for example,Campylobacter is the second leading cause of pediatric diarrhea with infants and one year olds experiencing1.2and0.4 episodes per year,respectively[2].Although most Campylobacter-associated diarrhea is self-limited,complications can occur.One complication is Guillain-Barre´Syndrome(GBS),an acute, symmetric,ascending paralysis that is estimated to occur30times for every100000Campylobacter cases.The case fatality ratio approaches10%[3–5].The link between GBS and campylobacterosis is based on studies suggesting that these enterobacteria are more often isolated from GBS cases than controls along with findings that anti-Campylobacter serum antibodies occur more frequently in cases[6].Studies which have linked Campylobacter infection to GBS have been typically performed in developed countries where exposure to Campylobacter is rare and residents are likely immunologically naive to Campylobacter [1,6].Studies examining an association between Campylobacter infection and GBS are infrequently performed in the developing world,where in contrast to developed countries,infections with Campylobacter are common and residents are repeatedly exposed.In the current study,we examined Campylobacter as an agent for GBS inEgypt,a country endemic for campylobacterosis and compared these findings to those reported from developed countries. MethodsStudy PopulationAll patients admitted to Cairo and Alexandria University Hospitals and children admitted to Ain Shams Children’s Hospital between April2001and September2003with GBS or Miller-Fisher syndrome were eligible for enrollment.For GBS,each patient demonstrated a progressive,symmetric ascending paralysis with a relative sensory sparing in more than one extremity with hypo-or areflexia[7].For Miller-Fisher syndrome,a variant of GBS,patients demonstrated ophthalmoplegia,ataxia and areflexia[8].If a lumbar puncture was performed,cerebral spinal fluid was evaluated for protein and cell counts.Findings consistent with GBS included an elevated CSF protein(.0.55g/liter)with a normal CSF cell count (,10cells/mm3).A neurologist diagnosed each case.For each case,the next three consecutive age-and hospital-matched patients meeting selection criteria were eligible as controls. Controls were within two years of the case’s age,were admitted with an acute illness,and could not present with acute neuropathic symptoms.As we were estimating the frequency of diarrhea before an acute illness,controls like cases could have a history of diarrhea or present with diarrhea but could not have diarrhea as their primary reason for admission.As blood samples from cases were obtained before receiving plasmapheresis or intravenous immuno-globulin,similarly controls were excluded if they received blood or blood products up to12months before enrollment.Clinical data,blood,and three rectal swabs were collected from all subjects.For children and patients too ill to provide a medical history,the history was taken from a parent,spouse,or another adult family member.Nerve conduction studies were performed on each case.The study was approved by the Institutional Review Board of the US Naval Medical Research Unit No.3and the Egyptian Ministry of Health and Population.Voluntary written informed consent for participation was provided by a parent or another adult family member for all cases and controls less than18years of age and by the patient if the age was greater than or equal to18 years,the age of majority.If an adult patient was unable to provide consent due to severe illness,a spouse or another adult family member was consented on behalf of the patient. Electrophysiological DataA Nerve Conduction Velocity(NCV)test was performed using conventional techniques and each patient was categorized as primary demyelinating,primary axonal,inexcitable,equivocal,or normal using published criteria[9].One investigator(IK) standardized testing at each hospital.Microbiologic InvestigationsCampylobacter isolation was based on techniques suggested elsewhere[10].Three rectal swabs were collected from each patient.Two swabs were placed in Cary-Blair transport media and one swab in Campy-Thio-Broth.Specimens were refrigerated at 4u to6u C and transported within three days to the US Naval Medical Research Unit No.3(NAMRU-3)laboratory in Cairo. At NAMRU-3,swabs from the Cary-Blair transport tubes were streaked on Campylobacter Selective Agar with Preston antibiotic supplement(CA),charcoal cefoperazone deoxycholate agar (CCDA),Shigella-Salmonella Agar(SS),and MacConkey’s Agar (MAC)plates.Campylobacter-Thio tubes were incubated at42u C for two hours then inoculated on Campylobacter selective agar plates.The CA and CCDA plates were incubated at42u C under microaerophilic conditions for up to72hours and checked every 24hours for growth.A case was Campylobacter negative,if no growth was found after72hours.When Campylobacter-like colonies were observed on the CA and/ or CCDA plates,an oxidase test and Gram stain were performed followed by re-streaking onto blood agar plates.After24hours of microaerophilic growth,isolates were tested for hippurate hydrolysis.Hippurate positive colonies(presumptive identification for C jejuni)were sub-cultured onto three Mueller-Hinton blood agar plates with filters,incubated at42u C for24to48hours under microaerophilic conditions.Indoxyl Acetate Hydrolysis(IAH)was conducted on hippurate-negative colonies followed by catalase testing if the IAH was positive.IAH/catalase positive organisms were classified as C coli whereas IAH positive/catalase negative colonies were classified as C upsaliensis.Multiple Campylobacter isolates from a pure plate were pooled and inoculated into three, 1.5mls of trypticase soy broth supplemented with15%sterile glycerol and frozen at270u C.Serum Immune ResponsesBlood samples were collected for cases within one day of admission(Interquartile Range(IQR):0to2)and for controls on the day(IQR:0to1)of enrollment.Serum was separated and stored at270u C until assayed by enzyme linked immunoassay (ELISA)described in detail elsewhere[11,12].In brief,a glycine extract(GE)of proteins[13]from a reference strain,C jejuni81–176,was prepared.The extract was used to coat wells of MaxiSorp 96-well immuoplates(NUNC)at3m g/ml or,for control wells,at 10m g/ml of bovine serum albumin(Sigma Chemicals).Serum IgM and IgG were measured by ELISA that used peroxidase-conjugated isotype-specific goat anti-human immunoglobulin. Endpoint titers are expressed as the reciprocal of the highest dilution giving a net absorbance(antigen well–BSA control well) value of0.15at OD405.Antiganglioside IgG ResponsesAntiganglioside serum IgG was determined by ELISA with minor modification of methodology reported by Willison et al [14].Briefly,MaxiSorp96-well immuoplates were coated with 0.5m g of each ganglioside GM1,GM2,GD1a,Gd1b or Gt1b (Sigma Chemicals).Negative control wells were coated with methanol.After blocking with1%BSA,plates were washed with PBS-T(PBS with.05%Tween20)and100m l of1:100diluted samples were added in duplicate to each ganglioside and control wells.Following overnight incubation at4u C,plates were washed6 times and100m l of0.1%BSA containing0.25m g of HRP conjugated goat anti-human IgG(KPL)was added and incubated for two hours at4u C.Following washing,100m l of substrate ABTS+H2O2(KPL)was added to each well and after an additional30minutes incubation at room temperature,absor-bance(OD405)was measured(Molecular Devices).Net OD was calculated by subtracting the OD values of control well from the ganglioside-coated wells.Data are expressed as net OD405at1:100 serum dilutions.Campylobacter Speciation and SerotypingBiochemical speciation of Campylobacter isolates was confirmed using a two-step Polymerase Chain Reaction(PCR)based test [15].A region in the16S rRNA was amplified and digested with the endonucleases DdeI,BsrI,and TaqI.Resulting PCR products were separated by gel electrophoresis,stained with ethidium bromide and visualized by UV.Patterns were then evaluated by comparison to reference standards.Identification of C jejuni or Ccoli was confirmed by amplification of the hippurate gene(hipp)or the aspartyl kinase gene(asp).All Campylobacter isolates were serotyped using the methods of Penner and Lior[16,17]. DefinitionsSubjects were thought to possess luxury items if they owned three or more of the following:washing machine,sewing machine, oven,apartment,farmland,other land,or cell phone.Participants owned livestock if they kept goats,cows,ducks,pigeons,etc. Patients produced antiganglioside antibodies if the net OD (gangliosides coated wells–control wells)readings was..01,the detectable limit of the assay,while those not producing antiganglioside antibodies were patients with an OD of#0.1. To be consistent with a previous study,a diarrhea case was a patient with a history of diarrhea in the three months preceding admission[18].Campylobacter-associated diarrhea was defined as isolating Campylobacter from a patient reporting diarrhea. Statistical AnalysisA conditional multivariate logistic regression model that accounts for the lack of sampling independence from matching was used to compare cases to controls for demographic characteristics,diarrhea prevalence,etc.[19].A univariate odds ratio was obtained by adding a single dependent(i.e.,case or controls status)and independent variable to the model.When controlling for confounders,additional independent variables were added including,unless stated otherwise,gender,livestock ownership,and possession of luxury items.When doing a subgroup analysis of cases and controls(e.g., cases and control with diarrhea)matching by age and hospital was incomplete.In this situation,we employed a multivariate unconditional regression and fit age and hospital of admission. Because age was not normally distributed,this variable was fit as a categorical variable:,5year old(infants and toddlers),5to,13 years(children),13to,18(teenagers),and18or older(adults). For all models,the95%confidence intervals and p-values were obtained from the model parameters.When comparing cases to controls by IgM serum antibody titers,we used linear regression with Generalized Estimating Equations because of matching[20,21].Univariate models included a single dependent(i.e.,normal log of serum IgM titer).For all multivariate models,gender,livestock ownership,and possession of luxury items were included.When completing a subgroup analysis(e.g.,only cases and control with diarrhea)age and hospital of admission were added to the model.When analyzing only case data(e.g.,Campylobacter excretion),an unconditional multivariate logistic regression was used.The values for univariate and multivariate models were calculated as the conditional regression model described earlier.The distribution of Campylobacter species and serotypes for cases and controls were compared using a Fisher’s exact test since cell sizes were small(i.e.,,5).A sign rank test was employed to compare the distribution of ages between cases and controls expressing Campylobacter and the distribution of days from admission to enrollment.To determine if diarrhea was more common during warmer months and whether males were more likely to have GBS than females,the exact p-value of a binomial test of significance with binomial probability under the null hypothesis of0.5was used[22].A chi-square test was employed to compare the clinical characteristics(e.g.,mucoid stools,fever)of cases and controls reporting diarrhea.Statistical significance was two tailed with P,0.05.For analyses, SAS version9.1(SAS Institute,Inc,Cary,North Carolina)or StatXact version4.01(Cytel Software Corporation,Cambridge, Massachusetts)was used.For graphing,SigmaPlot version8.0 (SPPS,Inc,Chicago,Illinois)was employed.ResultsEnrolleesNeurologists identified138GBS patients of which133(96.4%) including one case of Miller-Fisher Syndrome were enrolled(one declined to participate,three had normal NCV,and one was infected with Shigella flexneria).Out of401matched-controls,374 (93.3%)were enrolled(eight did not meet inclusion criteria and19 were infected with Salmonella spp.)Rectal swabs and serum samples were obtained from all enrollees.Description of CasesOf the cases,120(90.2%)received a NCV test(4died and9left the hospital before testing)with76(63.3%)found to have primary demyelinating disease,17(14.2%)had primary axonal disease,15Table1.Characteristics of cases and controls enrolled in study of Campylobacter infection and Guillain-Barre´Syndrome,the Arab Republic of Egypt,April2001through September2003.Population characteristics All Cases and controls History of diarrhea Campylobacter positiveCases(n=133)Controls(n=374)Cases(n=39)Controls(n=83)Cases(n=14)Controls(n=26) Age(years)a,b4(2to9)4(1to9)4(1to19)3(1to10)4(2.5to9) 1.5(1.0to6.0)Male(%)60.257.056.451.878.753.9Own livestock(%)51.535.1c39.532.542.950.0Possessed luxury items(%)d28.623.828.233.77.142.3eAin Shams University,Children’s12.012.320.522.914.311.5Cairo University36.835.818.019.350.038.5Alexandria University51.151.961.557.835.750.0a Median(interquartile range).b Patients were matched to controls for age(62years)and hospital for all cases and controls;matching was incomplete when analyzing subgroups(e.g.,Cases and controls with diarrhea).c P=.002;Odds Ratio=1.86(95%CI:1.25to2.78),univariate unconditional logistic regression.d Owned three or more luxury items(e.g.,cell phone,car).e P=.04;Odd Ratio=0.10(95%CI:0.01to0.93),univariate unconditional logistic regression.doi:10.1371/journal.pone.0003674.t001(12.5%)had inexcitable disease and test results were equivocal for 12(10.0%)patients.GBS showed no seasonality(P=.20).GBS was more common in males(60.2%,P=0.02).Twenty-one(15.8%)cases required mechanical ventilation and11(8.3%)cases died.Case and Control CharacteristicsCases ranged in age from7months to77years with a median of4 years(IQR:2to9)while controls ranged from1month to75years with a median of4years(IQR:1to9).(Table1)Cases and controls appeared similar for gender and possession of luxury items.Cases were more likely to own livestock(P=0.002).Most cases and controls were from Alexandria University Hospital(51.1%),followed by Cairo University Hospitals(36.9%),and Ain Shams University Children’s Hospital(12.0%).Median age of cases at the admitting hospital was5 (IQR:2to13),4(IQR:2to5),and2(IQR:1to6.5)years for Alexandria,Cairo,and Ain Shams Pediatric Hospitals,respectively. Diarrhea EpisodesThirty-nine(29.5%)cases and83(22.5%)controls(1case and5 controls had incomplete diarrhea data)reported having diarrhea with cases being1.69(95%CI:1.04to2.75,P=0.03)times more likely to have diarrhea after adjusting for confounding variables. Diarrhea was more common during warmer months but only reached statistical significance for controls,63.9%(P=0.015),but not for cases,61.5%(P=.20).The number of days between diarrhea onset and hospital admission was statistically similar for cases(median=14,IQR:2to35)and controls(median=14,IQR: 7to28).Among case and controls reporting diarrhea,there were no statistically significant differences for reports of mucoid stools (38.2%vs.51.9%),bloody stools(14.3%vs.11.5%),fever(43.2% vs.58.7%),or vomiting(18.4%vs.30.1%).Campylobacter Isolation and SerotypesCampylobacter isolates were identified from14(10.5%)cases and 26(7.0%)controls(OR a=1.66,95%CI:0.78to3.51,P=.19).Of the Campylobacter isolates,C jejuni was isolated from11(78.6%) cases and23(88.5%)control,while the remaining isolates were C coli(P=0.65for distribution by species).Six(42.8%)of14case isolates and7(28.0%)of25control isolates(one control had missing data)had diarrhea.We did not detect an association between Campylobacter isolation and diarrhea.There were26Penner:Lior serogroups identified.(Table2)Of these serogroups,4(3.0%)case strains and1(0.3%)control strainwere Penner:Lior41:27,a C jejuni strain(P=0.02).None of the other25serogroups were statistically associated with GBS. Serum Antibody ResponsesWe detected significantly higher geometric mean,IgM serum antibody titers in cases than controls(Geometric Mean Titers (GMT):8.18vs.7.25,P,0.0001).(Figure1)Cases had higher GMT when restricting the analysis to cases and controls reporting diarrhea(GMT:7.89vs.7.29,P=0.01)or excreting Campylobacter (GMT:8.51vs.7.43,P=0.01).These differences remained statistically significant after adjusting for confounders. Antiganglioside ResponsesExcept for GM2,the proportion of cases producing autoanti-bodies against gangliosides was statistically greater for cases than controls.(Table3)The odds of having antiganglioside antibodies for cases was2.79(95%CI:1.77to4.40,P,0.0001),4.39(95% CI:2.59to7.45,P=0.047),2.95(1.77to4.90,P,0.0001),and 2.56(95%CI:1.29to5.07,P=0.007)for GM1,GD1a,GD1b, and GT1b,respectively.When limiting the analysis to patients reporting diarrhea, antiganglioside antibody production was again higher in cases than controls except for GM2.However,the difference was only statistically significant for autoantibodies against GD1a (ORa=5.18,95%CI:1.76to15.68,P=0.0037).When further restricting the analysis to cases and controls excreting Campylobac-ter,serum antibodies to gangliosides appeared substantially higher in cases than controls and three of the five ganglioside types were statistically significant.Cases were5.17(95%CI:1.03to26.07, P=0.047),7.89(95%CI:1.16to53.65,P=0.04),and23.84(95% CI:2.46to231.25,P=0.006)times more likely than control to produce autoantibodies against GM1,GD1a,and GD1b, respectively.DiscussionGBS is believed to be an autoimmune disease.During infection, antibodies may be produced against lipo-oligosaccharides mole-cules on the surface of some Campylobacter strains that mimic the Table2.Percent of each Penner and Lior(Penner:Lior) Campylobacter serogroup isolated from Guillain-Barre´Syndrome cases and patient-controls,the Arab Republic of Egypt,April2001through September2003.Penner:Lior Group Cases a(n=133)Controls(n=374)P-value b%(n)%(n)1(10,32,47):42C c0(0)0.3(1) 1.01(10,44,47):UT C0(0)0.3(1) 1.01:UT J0(0)0.5(2) 1.02:125J0(0)0.3(1) 1.04(13,50):7J0(0)0.3(1) 1.05(32):22J0(0)0.3(1) 1.05:UT J0(0)0.5(2) 1.010(47):69J0(0)0.3(1) 1.013:36J0.8(1)0.3(1)0.513(50,65):7J0.8(1)0(0)0.314:57C0(0)0.3(1) 1.019:UT J0.8(1)0(0)0.319(33):UT J0.8(0)0.3(1) 1.022:UT J0.8(1)0.5(2) 1.024:110C0(0)0.3(1) 1.032:22J0(0)0.3(1) 1.034:46C0.8(1)0(0)0.337(56):28C0(0)0.3(1) 1.040:80J0.8(1)0(0)0.341:27J 3.0(4)0.3(1)0.0242:19J0(0)0.5(2) 1.046(47):95C0.8(1)0(0)0.346(47):UT C0(0)0.3(1) 1.049:97C0(0)0.3(1) 1.053:UT J0(0)0.3(1) 1.056:UT C 1.5(2)0(0)0.07a One case specimen and two controls specimens were not serotyped.b Fisher’s exact test.c Subscript‘‘J’’=C jejuni and subscript‘‘C’’=C coli.doi:10.1371/journal.pone.0003674.t002molecular structure of gangliosides [23].These autoantibodies are then directed against peripheral nerve tissue leading to myelin inflammation,conduction block,and in some cases,axonal degradation.As not all Campylobacter infections lead to GBS,the agent and host factors that induce pathogenesis remain unclear.This study was implemented in Egypt where residents repeatedly experience Campylobacter -associated diarrhea [2,24,25].Since most studies of Campylobacter and GBS have been completed in western developed countries,where infection and immunity is uncommon,we had an opportunity to examine the associationofFigure 1.Natural log of IgM serum antibody titers against Campylobacter among Guillain-Barre´Syndrome cases and patient-controls and among cases and controls reporting diarrhea or excreting Campylobacter,the Arab Republic of Egypt,April 2001through September 2003.doi:10.1371/journal.pone.0003674.g001Table 3.Odds of having IgM serum antibodies against GMI,GM2,GD1a,GD1b,and GT1b gangliosides in Guillain-Barre´Syndrome cases and patient-controls for all cases and controls,for patients reporting diarrhea,and for patients excreting Campylobacter ,the Arab Republic of Egypt,April 2001through September 2003.AntigangliosideAntibodiesAll cases and controls History of diarrhea Campylobacter positive Cases (n =133)Controls (n =374)Adjusted Odds Ratio aCases (n =39)Controls (n =83)Adjusted Odds Ratio b Cases(n =14)Controls (n =26)Adjusted Odds Ratio c GM145.925.9 2.79(1.77to 4.40)d,e 35.926.5 1.62(0.70to 3.76)50.015.4 5.17(1.03to 26.07)f GM211.313.70.77(0.41to 1.47) 2.616.90.14(0.02to 1.12)7.111.50.50(0.04to 5.92)GD1a 35.311.5 4.39(2.59to 7.45)e 28.29.6 5.03(1.67to 15.18)g 42.97.77.89(1.16to 53.65)h GD1b 30.813.1 2.95(1.77to 4.90)e 18.015.6 1.37(0.48to 3.93)57.17.723.84(2.46to 231.25)i GT1b14.36.72.56(1.29to 5.07)j7.76.01.35(0.29to 6.36)28.63.96.22(0.60to 64.97)a Conditional logistic regression controlling for age,gender,ownership of farm animals,and ownership of luxury items.bUnconditional logistic regression controlling for age,gender,livestock ownership,and possession of luxury items.cUnconditional logistic regression controlling for possession of luxury items.Other variable were excluded because of sparse data.dOdds Ratio (95%CI).e,.0001.fP =0.047.gP =.004.hP =0.04.iP =0.006.jP =.007.doi:10.1371/journal.pone.0003674.t003Campylobacter and GBS were residents have opportunities for repeated exposure to Campylobacter.When limiting our analysis to hospitals serving both children and adults,most GBS cases occurred in toddlers.This observation and observations from other developing countries contrasts[26] reports from developed countries where GBS is primarily an adult illness[1].The age-specific incidence of campylobacterosis which suggests a higher incidence in children living in developing countries and a higher incidence in adults in developed countries appear to correlate with the age-specific incidence of GBS.We observed that patients in contact with livestock appeared at increased risk of GBS suggesting that animal husbandry may be a hazard for GBS in Egypt.We have previously demonstrated in Egypt that exposure to farm animals increases the risk of Campylobacter infection in children[2],which may link animal husbandry to GBS.More than one in five controls reported diarrhea and controls had IgM antibodies against Campylobacter antigens further support-ing the view that Campylobacter infection was common.Still,GBS patients were69%more likely to have diarrhea and had significantly higher levels of serum antibodies against Campylobacter and several nerve gangliosides.These results suggest that GBS cases were more likely to be exposed to Campylobacter,some of which may have been neruopathogenic strains that express lipo-oligosaccharide mimics[3,27].As Campylobacter exposure was more common in this setting,we were able to compare immune responses between Campylobacter-positive cases and Campylobacter-positive controls.Despite currently excreting Campylobacter,suggesting current exposure,we detected significantly raised anti-Campylobacter antibody titers and anti-ganglioside antibodies in cases.A more vigorous antibody-mediated immunity in cases relative to controls may have been due to a greater proportion of case strains expressing lipopolysac-charide mimics or other antigenic variations[28],cases had a greater genetic susceptibility or other host factors to a virulent infection.However,studies of a genetic predisposition to GBS, such as HLA type,have had limited success[29,30].We identified a diversity of Penner:Lior serotypes but did not identify a Campylobacter serotype associated with a significant number of GBS cases as has been reported elsewhere[31,32].A Penner serotype O:41(i.e.,41:27),C jejuni,was statistically associated with GBS.This serotype has been isolated from GBS cases in South Africa[33,34]and is reported to have lipopolysac-charides that mimic the GM1ganglioside[35].Penner serotypes O:1,O:2,O:4,O:10,and O:37were recovered,and these strains have been reported to be associated with GBS,but we found these isolates only in control stools[3,18,36–39].This observation demonstrates the need for studies with comparison populations. The severity of GBS in Egypt appears similar to that reported from developing countries[40].The proportion ventilated,about 16%,and the proportion that died,about8%,is similar to the 20%ventilation rate and5%to10%case fatality ratio suggested for developed countries[5,41].Before stating our conclusions,we identify study limitations.We have shown that Campylobacter are excreted for about14days after infection in Egypt,and it is likely that patient stopped excreting Campylobacter before admission[2].Thus,Campylobacter excretion is likely higher in cases than reported here.As we interviewed hospital patients,and they were told the study objectives during informed consent,it may be that recall bias increased the frequency of diarrhea reports.Our conclusions could have been inaccurate due to enrollment or case-ascertainment bias,but all cases of acute flaccid paralysis were evaluated,and we had96% enrollment.Case ascertainment,clinical evaluation,and study implementation could have differed between hospitals thereby biasing the results.To mitigate these differences,we employed identical training,uniform study specific procedures,and central-ized supervision.In conclusion,Campylobacter isolation rates and diarrhea histories in our Egyptian patient population suggested that Campylobacter-associated infections are not rare.Still,even with widespread exposure to Campylobacter,Campylobacter infections appeared associated with induction of antiganglioside antibodies that may have triggered paralysis.AcknowledgmentsMs.Manal Mostafa and Dr.Khaled Hassan,NAMRU3,for assisting with the data management and analysis and Esteban Klaus and Mohammed Salah Motawea for immunology assays.Author ContributionsConceived and designed the experiments:TW IAAM BG SB AH IK TO JS DAS RF.Performed the experiments:TW IAAM BG SB AH IK TO JS LKN LP.Analyzed the data:TW IAAM SB JS LKN DAS RF. Contributed reagents/materials/analysis tools:BG SB AH JS LP DAS RF.Wrote the paper:TW IAAM BG SB AH IK TO JS LKN LP RF. Bacteriologist for the study:SDP.Conceived the bacteriology protocols and also assisted with the epidemiological design,assisted with performing the experiment,contributed reagents and materials,and wrote the bacteriology sections of the manuscript:SDP.One of the neurologists on the study:HEK.Performed the study in his department,contributed materials,and reviewed the manuscript:HEK.Oversaw the enrollment of cases and controls including the diagnosis of GBS:HEK.References1.Blaser MJ(1997)Epidemiologic and clinical features of Campylobacter jejuniinfections.J Infect Dis176Suppl2:S103–105.2.Rao MR,Naficy AB,Savarino SJ,Abu-Elyazeed R,Wierzba TF,et al.(2001)Pathogenicity and convalescent excretion of Campylobacter in rural Egyptian children.Am J Epidemiol154:166–173.3.Nachamkin I,Allos BM,Ho T(1998)Campylobacter species and Guillain-Barresyndrome.Clin Microbiol Rev11:555–567.4.McCarthy N,Giesecke J(2001)Incidence of Guillain-Barre Syndrome followingInfection with Campylobacter jejuni.Am J Epidemiol153:610–614.5.de Jager AE,Sluiter HJ(1991)Clinical signs in severe Guillain-Barre syndrome:analysis of63patients.J Neurol Sci104:143–150.6.Allos BM(1998)Campylobacter jejuni infection as a cause of the Guillain-Barresyndrome.Infect Dis Clin North Am12:173–184.7.Ropper AH(1992)The Guillain-Barre syndrome.N Engl J Med326:1130–1136.8.Bushra JS(2000)Miller Fisher syndrome:an uncommon acute neuropathy.JEmerg Med.pp427–430.9.Alam TA,Chaudhry V,Cornblath DR(1998)Electrophysiological studies in theGuillain-Barre syndrome:distinguishing subtypes by published criteria.Muscle Nerve21:1275–1279.10.Nachamkin I(1997)Microbiologic approaches for studying Campylobacterspecies in patients with Guillain-Barre syndrome.J Infect Dis176Suppl2: S106–114.11.Baqar S,Bourgeois AL,Schultheiss PJ,Walker RI,Rollins DM,et al.(1995)Safety and immunogenicity of a prototype oral whole-cell killed Campylobacter vaccine administered with a mucosal adjuvant in non-human primates.Vaccine 13:22–28.12.Walz SE,Baqar S,Beecham HJ,Echeverria P,Lebron C,et al.(2001)Pre-exposure anti-Campylobacter jejuni immunoglobulin a levels associated with reduced risk of Campylobacter diarrhea in adults traveling to Thailand.Am J Trop Med Hyg65:652–656.13.Logan SM,Trust TJ(1983)Molecular identification of surface protein antigensof Campylobacter jejuni.Infect Immun42:675–682.14.Willison HJ,Veitch J,Swan AV,Baumann N,Comi G,et al.(1999)Inter-laboratory validation of an ELISA for the determination of serum anti-ganglioside antibodies.Eur J Neurol6:71–77.15.Marshall SM,Melito PL,Woodward DL,Johnson WM,Rodgers FG,et al.(1999)Rapid identification of Campylobacter,Arcobacter,and Helicobacter isolates by PCR-restriction fragment length polymorphism analysis of the16S rRNA gene.J Clin Microbiol37:4158–4160.。